


10/826,743

=> d l2; d his; log y  
L2 HAS NO ANSWERS  
L1 STR



G1 O,S

G2 O,S

Structure attributes must be viewed using STN Express query preparation.  
L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 12:10:21 ON 29 JUN 2005)

FILE 'REGISTRY' ENTERED AT 12:10:33 ON 29 JUN 2005

L1 STRUCTURE UPLOADED

L2 QUE L1

L3 26 S L2

L4 598 S L2 FUL

FILE 'CAPLUS' ENTERED AT 12:11:12 ON 29 JUN 2005

L5 31 S L4

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	154.49	316.03
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-22.63	-22.63

STN INTERNATIONAL LOGOFF AT 12:13:04 ON 29 JUN 2005

L5 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2005:409553 CAPLUS  
 DN 142:459118  
 TI HCV NS3-NS4A protease resistance mutants affecting the activity of  
 NS3-NS4A inhibitory drugs VX-950 and BILN2061 and structure-based anti-HCV  
 drug design  
 IN Lin, Chao; Lin, Kai  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO PCT Int. Appl., 113 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005042570	A1	20050512	WO 2004-US35839	20041027
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005136400	A1	20050623	US 2004-974558	20041027
PRAI	US 2003-514740P	P	20031027		
	US 2003-525222P	P	20031126		
	US 2004-561662P	P	20040413		

AB The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment. In particular embodiments, in vitro resistance studies of NS3-4A mutants at the residues Ala156 and Asp168 of NS3-4A protease domain using a subgenomic replicon system to compare VX-950 with another HCV NS3-4A protease inhibitor, BILN 2061, are reported. Distinct drug-resistant substitutions, including Ala156 to Ser or Val or Thr, and Asp168 to Glu or Val or Ala or Gly or Tyr, are identified in the HCV NS3 serine protease domain for both inhibitors. The resistance conferred by these mutations is confirmed by characterization of the mutant enzymes and replicon cells that contain the single amino acid substitutions. The major BILN 2061-resistant mutations at Asp168 are fully susceptible to VX-950, and the dominant resistant mutation against VX-950 at Ala156 remains sensitive to BILN 2061. Modeling anal. suggests that there are different mechanisms of resistance to VX-950 and BILN 2061.

IT 300832-84-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)

(HCV NS3-NS4A protease resistance mutants affecting activity of  
 NS3-NS4A inhibitory drugs VX-950 and BILN2061 and structure-based  
 anti-HCV drug design)

RN 300832-84-2 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
 acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16  
 ,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-  
 4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.


10/826,743

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2005:283507 CAPLUS  
 DN 142:355580  
 TI Preparation of macrocyclic peptides active against the hepatitis C virus  
 IN Llinas-Brunet, Montse; Bailey, Murray; Bhardwaj, Punit; Forgione,  
 Pasquale; Ghio, Elise; Goudreau, Nathalie; Halmos, Teddy; Rancourt, Jean  
 PA Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim  
 Pharma GmbH & Co Kg  
 SO PCT Int. Appl., 128 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005028501	A1	20050331	WO 2004-CA1658	20040920
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005080005	A1	20050414	US 2004-945518	20040920
PRAI	US 2003-504839P	P	20030922		
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Macrocyclic peptides I [X is CH or N; X1 is a 5- to 10-atom (un)saturated alkylene chain optionally containing 1-3 heteroatoms O, S, N or substituted imino; L0 is H, OH, alkoxy, NH2 or alkylamino; L1, L2 are H (but not both), independently halo, alkyl, alkynyl, alkoxy, alkylthio, -sulfinyl or -sulfonyl; or L0/L1 or L0/L2 may form rings; R1 is OH or a sulfonylamino group; R2 is (un)substituted aryl or heterocyclyl; R3 is OH, NH2 or substituted amino; R4 is H or 1-3 substituents alkyl, haloalkyl, alkoxy, OH, halo, amino, oxo, thio or alkylthio (with provisos)] or their pharmaceutically-acceptable salts or esters were prepared as inhibitors of the hepatitis C virus (HCV) NS3 protease. Thus, compound II was prepared by a multistep sequence involving olefin metathesis in formation of the macrocycle. Compds. of the invention such as II usually show IC50 values .ltorsim. 50 nM and EC50 values .ltorsim. 55 nM.

IT 849022-30-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of macrocyclic peptides active as hepatitis C virus inhibitors)

RN 849022-30-6 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-8-methyl-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




10/826,743

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



IT 849022-31-7P 849022-32-8P 849022-33-9P  
849022-34-0P 849022-35-1P 849022-36-2P  
849022-37-3P 849022-38-4P 849022-39-5P  
849022-40-8P 849022-41-9P 849022-42-0P  
849022-43-1P 849022-44-2P 849022-45-3P  
849022-46-4P 849022-47-5P 849022-48-6P  
849022-49-7P 849022-50-0P 849022-51-1P

10/826,743

849022-52-2P 849022-53-3P 849022-54-4P  
849022-55-5P 849022-56-6P 849022-57-7P  
849022-58-8P 849022-59-9P 849022-60-2P  
849022-61-3P 849022-62-4P 849022-63-5P  
849022-64-6P 849022-65-7P 849022-66-8P  
849022-67-9P 849022-68-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of macrocyclic peptides active as hepatitis C virus inhibitors)


RN 849022-31-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-8-methyl-4-  
quinolinyl]oxy]-6-[[[(cyclopentyloxy) carbonyl] amino]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-,  
(2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.


Double bond geometry as shown.

PAGE 1-A



PAGE 1-B








RN 849022-32-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-8-methyl-2-[2-[(2-methyl-1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.








RN 849022-33-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-8-methyl-2-[2-[(1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.








RN 849022-34-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[8-bromo-7-methoxy-2-[2-[(1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.








RN 849022-35-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[8-bromo-7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-6-[[[(cyclopentyl)oxy]carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.








RN 849022-36-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[8-chloro-7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-6-[[ (cyclopentyloxy) carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.







RN 849022-37-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[[8-chloro-7-methoxy-2-[2-[(1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-6-[[[(cyclopentyl)oxy]carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.










RN 849022-38-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2;3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-6,8-dimethyl-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.








RN 849022-39-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-6,8-dimethyl-2-[2-[(1-oxopropyl) amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.








RN 849022-40-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[[8-fluoro-7-methoxy-2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.








RN 849022-41-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[8-fluoro-7-methoxy-2-[2-[(1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.








RN 849022-42-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[[8-chloro-7-methoxy-2-[[2-[(1-oxobutyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.








RN 849022-43-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[8-bromo-7-methoxy-2-[[2-[(1-oxobutyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-6-[[[(cyclopentyl)oxy]carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.








RN 849022-44-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[[8-bromo-7-methoxy-2-[(2-methyl-1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.







RN 849022-45-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[[8-bromo-7-methoxy-2-[[[(1-methylethoxy) carbonyl] amino]-4-thiazolyl]-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.










RN 849022-46-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-[2-[(3,3-dimethyl-1-oxobutyl)amino]-4-thiazolyl]-8-(methylthio)-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.








RN 849022-47-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-[(cyclopentylacetyl)amino]-4-thiazolyl]-8-(methylthio)-4-quinolinyl]oxy]-6-[[[(cyclopentyl)oxy]carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.







RN 849022-48-6 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[8-(methylthio)-2-[2-[(1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.








RN 849022-49-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentylthio)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[2-[2-[(1-methylethyl)amino]-4-thiazolyl]-8-(methylthio)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 849022-50-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[8-(methylthio)-2-[2-[(1-oxobutyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.







RN 849022-51-1 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[2-[2-[(2-methyl-1-oxopropyl)amino]-4-thiazolyl]-8-(methylthio)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.







RN 849022-52-2 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[2-[2-[(1-methylethoxy)carbonyl]amino]-4-thiazolyl]-8-(methylthio)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.







RN 849022-53-3 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[8-(methylsulfonyl)-2-[2-[(1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.








RN 849022-54-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[2-[2-[(1-methylethyl) amino]-4-thiazolyl]-8-(methylsulfonyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-55-5 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[2-[2-[(2-methyl-1-oxopropyl)amino]-4-thiazolyl]-8-(methylsulfonyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


10/826,743

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-56-6 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[2-[2-[(1-methylethoxy)carbonyl]amino]-4-thiazolyl]-8-(methylsulfonyl)-4-quinolinyl]oxy]-5,16-dioxo-,

10/826,743


(2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-57-7 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-8-methyl-4-quinolinyl]oxy]-6-

10/826,743


[[ (cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-58-8 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16

10/826,743


,16a-tetradecahydro-2-[[8-methyl-2-[2-[(1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-59-9 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentyloxy)carbonyl]amino]-2-[[2-[2-[(3,3-dimethyl-1-

10/826,743


oxobutyl) amino]-4-thiazolyl]-8-methyl-4-quinolinyl]oxy]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-,  
(2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-60-2 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
acid, 6-[[ (cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16

10/826,743.


,16a-tetradecahydro-2-[[8-methyl-2-[2-[(2-methyl-1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



RN 849022-61-3 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16




10/826,743


,16a-tetradecahydro-2-[[8-methyl-2-[2-[[ (1-methylethoxy) carbonyl] amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-62-4 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentyloxy) carbonyl] amino]-2-[[8-ethynyl-2-[2-[(2-methyl-1-

10/826,743


oxopropyl)amino]-4-thiazolyl]-4-quinolinyloxy]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-,  
(2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-63-5 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
acid, 6-[[ (cyclopentyloxy) carbonyl] amino]-2-[[8-ethynyl-2-[2-[(1-

10/826,743


oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-,  
(2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-64-6 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[[8-ethynyl-2-[2-[(1-

10/826,743


methylethyl) amino]-4-thiazolyl]-4-quinolinyl]oxy]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-,  
(2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-65-7 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
acid, 6-[[ (cyclopentyloxy) carbonyl] amino]-2-[[2-[2-[(3,3-dimethyl-1-

10/826,743


oxobutyl)amino]-4-thiazolyl]-8-ethynyl-4-quinolinyl]oxy]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-,  
(2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-66-8 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15

10/826,743

,16,16a-hexadecahydro-2-[[[7-methoxy-8-methyl-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)






RN 849022-67-9 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[[7-methoxy-8-methyl-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A





RN 849022-68-0 CAPLUS  
 CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[[7-methoxy-8-methyl-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-14a-[[[(1-methylcyclopropyl)sulfonyl]amino]carbonyl]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)



IT 849022-04-4P 849022-05-5P 849022-06-6P  
 849022-07-7P 849022-08-8P 849022-09-9P  
 849022-10-2P 849022-11-3P 849022-12-4P  
 849022-13-5P 849022-14-6P 849022-15-7P  
 849022-16-8P 849022-17-9P 849022-18-0P  
 849022-19-1P 849022-20-4P 849022-21-5P  
 849022-22-6P 849022-23-7P 849022-24-8P  
 849022-25-9P 849022-26-0P 849022-27-1P  
 849022-28-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of macrocyclic peptides active as hepatitis C virus inhibitors)

RN 849022-04-4 CAPLUS



CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(methoxycarbonyl)-8-methyl-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A










RN 849022-05-5 CAPLUS  
 CN Cyclopropa[el]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-carboxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, 14a-methyl ester, monosodium salt, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.






● Na




RN 849022-06-6 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-(diazoacetyl)-7-methoxy-8-methyl-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-07-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(bromoacetyl)-7-methoxy-8-methyl-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-08-8 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-8-methyl-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-09-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-8-methyl-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 849022-10-2 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[8-bromo-2-(bromoacetyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 849022-11-3 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[2-(methoxycarbonyl)-8-(methylthio)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-12-4 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-carboxy-8-(methylthio)-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, 14a-methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.




PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 849022-13-5 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-(diazoacetyl)-8-(methylthio)-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 849022-14-6 CAPLUS  
 CN Cyclopropan[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(bromoacetyl)-8-(methylthio)-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 849022-15-7 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[2-(methoxycarbonyl)-8-(methylsulfonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-16-8 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-carboxy-8-(methylsulfonyl)-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, 14a-methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/826,743

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-17-9 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-(diazoacetyl)-8-(methylsulfonyl)-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


10/826,743

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-18-0 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
acid, 2-[[2-(bromoacetyl)-8-(methylsulfonyl)-4-quinolinyl]oxy]-6-  
[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-  
tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-  
(9CI) (CA INDEX NAME)


10/826,743

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 849022-19-1 CAPLUS  
CN Cyclopropan[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[2-(methoxycarbonyl)-8-methyl-4-quinolinyl]oxy]-

10/826,743


5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



RN 849022-20-4 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-carboxy-8-methyl-4-quinolinyl)oxy]-6-[[ (cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-




10/826,743


tetradecahydro-5,16-dioxo-, 14a-methyl ester, monosodium salt,  
(2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



PAGE 2-A

● Na






RN 849022-21-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-(diazoacetyl)-8-methyl-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Double bond geometry as shown.






RN 849022-22-6 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(bromoacetyl)-8-methyl-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.








RN 849022-23-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[8-methyl-2-[2-[[[(1-methylethoxy)carbonyl]amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Double bond geometry as shown.






RN 849022-24-8 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[8-ethynyl-2-(methoxycarbonyl)-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.








RN 849022-25-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-carboxy-8-ethynyl-4-quinolinyl)oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, 14a-methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.








RN 849022-26-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-(diazoacetyl)-8-ethynyl-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.







RN 849022-27-1 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(bromoacetyl)-8-ethynyl-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.










RN 849022-28-2 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[8-ethynyl-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.






RE.CNT 5      THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2005:265044 CAPLUS  
DN 142:441083  
TI Dynamics and structure-based design of drugs targeting the critical serine protease of the hepatitis C virus - from a peptidic substrate to BILN 2061  
AU LaPlante, Steven R.; Llinas-Brunet, Montse  
CS Research and Development, Department of Chemistry, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2G5, Can.  
SO Current Medicinal Chemistry: Anti-Infective Agents (2005), 4(2), 111-132  
CODEN: CMCAFL; ISSN: 1568-0126  
PB Bentham Science Publishers Ltd.  
DT Journal; General Review  
LA English  
AB A review. Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide. Although a treatment of limited efficacy exists, there is an urgent need for potent antivirals that can specifically target the viral proteins that are essential for replication. The authors recently reported the discovery of BILN 2061, a selective and potent inhibitor of the HCV NS3 protease. When administered to HCV infected patients for 2 days, BILN 2061 produced an unprecedented and rapid decrease in viral load, thus demonstrating the first proof-of-concept for a new class of HCV antiviral. The BILN 2061 family of compds. was rationally designed from a peptidic substrate using dynamics- and structure-based strategies. In this review, the authors present an overview of the novel strategies that led to the BILN 2061 family of compds. It includes the discovery of the original peptide as a lead, the identification of important substituents that directly contact the protease pocket, the determination of the free and protease-bound structure and dynamics features of the compds., and the rational use of such data for medicinal chemical purposes. Central to this was an ongoing effort to qual. elucidate the binding modes/roles of each substituent using a combination of data from NMR spectroscopy, structure-activity relationships, and x-ray crystallog. In addition to achieving the desired goal of initiating clin. trials with a potent inhibitor with good pharmacokinetic properties, the methodologies developed for targeting this unusual and difficult protease, which has a shallow and relatively featureless binding pocket, are expected to have general utility in other medicinal chemical efforts.  
IT 300832-84-2, BILN 2061  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(dynamics and structure-based design of drugs targeting critical serine protease of hepatitis C virus)  
RN 300832-84-2 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



RE.CNT 66

THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:1061024 CAPLUS

DN 142:385112

TI Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients

AU Hinrichsen, Holger; Benhamou, Yves; Wedemeyer, Heiner; Reiser, Markus; Sentjens, Roel E.; Calleja, Jose L.; Fornis, Xavier; Erhardt, Andreas; Croenlein, Jens; Chaves, Ricardo L.; Yong, Chan-Loi; Nehmiz, Gerhard; Steinmann, Gerhard G.

CS I. Medizinische Universitätsklinik, Kiel, Germany

SO Gastroenterology (2004), 127(5), 1347-1355

CODEN: GASTAB; ISSN: 0016-5085

PB Elsevier Inc.

DT Journal

LA English

AB Novel, potent, and well-tolerated hepatitis C virus (HCV) drugs are needed. BILN 2061 is a potent and specific inhibitor of HCV serine protease in vitro. Preclin. toxicol. data and studies in healthy volunteers supported the administration of BILN 2061 to patients with HCV infection. The antiviral efficacy, pharmacokinetics, and tolerability of 25, 200, and 500 mg BILN 2061 twice daily given as monotherapy for 2 days in 32 patients infected with chronic genotype 1 HCV infection and with minimal liver fibrosis (Ishak score of 0-2) were assessed in a placebo-controlled, double-blind pilot study. In 2 subsequent placebo-controlled studies of similar design, 200 mg BILN 2061 twice daily was administered for 2 days to 10 patients with advanced liver fibrosis (Ishak score of 3 or 4) and to 10 patients with compensated cirrhosis (Ishak score of 5 or 6). Viral RNA redns. of 2-3 log<sub>10</sub> copies/mL were achieved in most of the patients. There was a trend toward a higher number of patients receiving 500 mg BILN 2061 achieving a viral RNA reduction  $\geq 3$  log<sub>10</sub> copies/mL as compared with patients receiving 25 mg BILN 2061. Advanced fibrosis or compensated cirrhosis did not affect the antiviral efficacy of BILN 2061. BILN 2061 was well tolerated in all studies. BILN 2061 is a well-tolerated and very active compound that reduced serum viral RNA concns. after 2 days of treatment in patients infected with genotype 1 HCV independent of the degree of fibrosis. Nevertheless, further clin. trials are on hold pending resolution of animal toxicity issues.

IT 300832-84-2, BILN 2061

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiviral efficacy of HCV serine protease inhibitor BILN 2061 in patients with hepatitis C)


RN 300832-84-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



RE.CNT 33

THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:997511 CAPLUS

DN 142:85717

TI Progress and development of small molecule HCV antivirals

AU Ni, Zhi-Jie; Wagman, Allan S.

CS Chiron Corporation, Emeryville, CA, 94608, USA

SO Current Opinion in Drug Discovery & Development (2004), 7(4), 446-459

CODEN: CODDDF; ISSN: 1367-6733

PB Thomson Scientific

DT Journal; General Review

LA English

AB A review. Hepatitis C virus (HCV) is a disease that has a growing impact worldwide. A combination therapy comprising interferon- $\alpha$  (IFN $\alpha$ ) and ribavirin represents the current standard treatment for chronic HCV infection, although it has demonstrated limited success and causes some serious side effects. Promising alternative approaches toward the control of HCV infection, and the development of new antiviral agents, include the use of NS3/4A serine protease and NS5B polymerase inhibitors. Successful proof-of-concept clin. trials of the NS3/4A protease inhibitor BILN-2061 have confirmed the usefulness of a peptidomimetic product-based approach, providing impetus for the generation of improved mols. Preclin. results from the development of HCV polymerase inhibitors, both nucleoside and non-nucleoside, are promising. This review provides an overview of recent progress in these areas, and discusses the potential of various approaches toward small mol. HCV antivirals.

IT 300832-84-2, BILN-2061

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(development of small mol. HCV antivirals)


RN 300832-84-2 CAPLUS



CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A





RE.CNT 101 THERE ARE 101 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L5 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:940427 CAPLUS

DN 141:388064

TI The design of a potent inhibitor of the hepatitis C virus NS3 protease:  
BILN 2061 - From the NMR tube to the clinic

AU Tsantrizos, Youla S.

CS Research and Development, Boehringer Ingelheim (Canada) Ltd., Laval, QC,  
H7S 2G5, Can.

SO Biopolymers (2004), 76(4), 309-323

CODEN: BIPMAA; ISSN: 0006-3525

PB John Wiley & Sons, Inc.

DT Journal; General Review

LA English

AB A review. The virally encoded serine protease NS3/NS4A is essential to the life cycle of the hepatitis C virus (HCV), an important human pathogen causing chronic hepatitis, cirrhosis of the liver, and hepatocellular carcinoma. Until very recently, the design of inhibitors for the HCV NS3 protease was limited to large peptidomimetic compds. with poor pharmacokinetic properties, making drug discovery an extremely challenging endeavor. In our quest for the discovery of a small-mol. lead that could block replication of the hepatitis C virus by binding to the HCV NS3 protease, the critical protein-polypeptide interactions between the virally encoded NS3 serine protease and its polyprotein substrate were investigated. Lead optimization of a substrate-based hexapeptide, guided by structural data, led to the understanding of the mol. dynamics and electronic effects that modulate the affinity of peptidomimetic ligands for the active site of this enzyme. Macrocyclic  $\beta$ -strand scaffolds were designed that allowed the discovery of potent, highly selective, and orally bioavailable compds. These mols. were the first HCV NS3 protease inhibitors reported that inhibit replication of HCV subgenomic RNA in a cell-based replicon assay at low nanomolar concns. Optimization of their biopharmaceutical properties led to the discovery of the clin. candidate BILN 2061. Oral administration of BILN 2061 to patients infected with the hepatitis C genotype 1 virus resulted in an impressive reduction of viral RNA levels, establishing proof-of-concept for HCV NS3 protease inhibitors as therapeutic agents in humans.

IT 300832-84-2, BILN 2061

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(design of potent inhibitor of hepatitis C virus NS3 protease BILN  
2061: from NMR tube to clinic)


RN 300832-84-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:927230 CAPLUS  
 DN 141:395807  
 TI Preparation of macrocyclic isoquinoline peptide inhibitors of hepatitis C virus  
 IN McPhee, Fiona; Campbell, Jeffrey Allen; Li, Wenying; D'Andrea, Stanley; Zheng, Zhizhen Barbara; Good, Andrew Charles; Carini, David J.; Johnson, Barry L.; Scola, Paul Michael  
 PA Bristol-Myers Squibb Company, USA  
 SO PCT Int. Appl., 280 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004094452	A2	20041104	WO 2004-US11824	20040416
	WO 2004094452	A3	20050519		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005090432	A1	20050428	US 2004-825693	20040416
PRAI	US 2003-463423P	P	20030416		
OS	MARPAT 141:395807				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention discloses macrocyclic isoquinoline peptides I [R1-R6 are independently H, alkyl, cycloalkyl, alkoxy, cyano, halo, hydroxy, alkanoyl, nitro, amino, carboxyl, alkylsulfonyl, etc.; R7 is NH2 or NR10R11, where R10 is alkyl, haloalkyl, carbamoyl, carboxy or thiocarboxy ester or an acyl group; R11 is H, alkyl or haloalkyl; R8, R9 are H or alkyl optionally substituted with halogen, alkoxy or haloalkoxy; Q is a saturated or unsatd. chain optionally containing one to three heteroatoms O, S(O)0-2, NH, alkylimino, cycloalkylimino, etc.; W is OH, NHS(O)1-2R12, where R12 is alkyl, cycloalkyl, aryl or heterocyclyl] or their pharmaceutically-acceptable enantiomers, diastereomers, salts, solvates or prodrugs and methods for using them to inhibit the hepatitis C virus (HCV). Thus, cyclic peptide II (Boc = tert-butoxycarbonyl) was prepared via peptide coupling and olefin metathesis cyclization reactions and showed IC50 and EC50 values <0.05  $\mu$ M in the HCV NS3/4A protease inhibition assay. Combination studies showed that treatment of replicon cells with an HCV NS3 protease inhibitor, compound II and Intron A and/or inhibitors targeting HCV NS5A and/or NS5B, yield additive to synergistic antiviral effects.

IT 790302-51-1P 790302-55-5P 790302-57-7P  
 790302-62-4P 790302-80-6P 790304-01-7P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of macrocyclic isoquinoline peptide inhibitors of hepatitis C virus)


RN 790302-51-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(1-isoquinolinylloxy)-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 790302-55-5 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-(1-isoquinolinylloxy)-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 790302-57-7 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-(1-isoquinolinylloxy)-5,16-dioxo-14a-[[[(1-propylcyclopropyl)sulfonyl]amino]carbonyl]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790302-62-4 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, 6-amino-N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(1-isoquinolinyloxy)-5,16-dioxo-, dihydrochloride, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A






RN 790302-80-6 CAPLUS

CN 5H-Cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecine-14a(11H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,13a,14,15,16,16a-dodecahydro-2-[(6-methoxy-1-isoquinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 790304-01-7 CAPLUS

CN Cyclopropanecarboxylic acid, N-[(1,1-dimethylethoxy) carbonyl]-L-homoseryl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-2-[(1Z)-3-hydroxy-1-propenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)



IT 790302-52-2P 790302-54-4P 790302-56-6P  
 790302-58-8P 790302-59-9P 790302-60-2P  
 790302-61-3P 790302-63-5P 790302-65-7P  
 790302-66-8P 790302-67-9P 790302-68-0P  
 790302-69-1P 790302-72-6P 790302-73-7P  
 790302-74-8P 790302-76-0P 790302-77-1P  
 790302-78-2P 790302-79-3P 790302-81-7P  
 790302-82-8P 790302-83-9P 790302-84-0P  
 790302-85-1P 790302-86-2P 790302-87-3P  
 790302-88-4P 790302-90-8P 790302-91-9P  
 790302-92-0P 790302-93-1P 790302-94-2P  
 790303-04-7P 790303-05-8P 790303-06-9P  
 790303-08-1P 790303-09-2P 790303-10-5P  
 790303-11-6P 790303-12-7P 790303-13-8P  
 790303-14-9P 790303-15-0P 790303-55-8P  
 790303-56-9P 790303-57-0P 790303-59-2P  
 790303-60-5P 790303-61-6P 790303-62-7P  
 790303-63-8P 790303-64-9P 790303-65-0P  
 790303-72-9P 790303-73-0P 790303-74-1P  
 790303-76-3P 790303-78-5P 790303-79-6P  
 790303-80-9P 790303-82-1P 790303-84-3P  
 790303-85-4P 790303-86-5P 790303-87-6P  
 790303-88-7P 790303-89-8P 790303-90-1P  
 790303-91-2P 790303-92-3P 790303-93-4P  
 790303-95-6P 790303-96-7P 790303-97-8P  
 790303-98-9P 790303-99-0P 790304-00-6P  
 790304-02-8P 790304-03-9P 790304-05-1P  
 790304-17-5P 790304-31-3P 790304-32-4P  
 790304-33-5P 790304-34-6P 790304-35-7P  
 790304-36-8P 790304-37-9P 790304-38-0P  
 790304-39-1P 790304-40-4P 790304-41-5P  
 790304-42-6P 790304-43-7P 790304-44-8P  
 790304-45-9P 790304-46-0P 790304-47-1P  
 790304-48-2P 790304-49-3P 790304-50-6P  
 790304-72-2P 790304-73-3P 790304-74-4P  
 790304-75-5P 790304-76-6P 790304-77-7P  
 790304-78-8P 790304-79-9P 790304-81-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocyclic isoquinoline peptide inhibitors of hepatitis C virus)

RN 790302-52-2 CAPLUS


CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-(1-isoquinolinylxy)-14a-

[[ (methylsulfonyl) amino] carbonyl]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 790302-54-4 CAPLUS


CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-(1-isoquinolinyloxy)-14a-[[[(1-methylethyl)sulfonyl]amino]carbonyl]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 790302-56-6 CAPLUS


CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-(1-isoquinolinyloxy)-5,16-dioxo-14a-[[[(1-(phenylmethyl)cyclopropyl)sulfonyl]amino]carbonyl]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)






RN 790302-58-8 CAPLUS

CN Carbamic acid, [(2R,6S,13aR,14aR,16aS)-octadecahydro-2-(1-isoquinolinylxy)-5,16-dioxo-14a-[[[(1-propylcyclopropyl)sulfonyl]amino]carbonyl]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadec-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790302-59-9 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-(1-isoquinolinylxy)-14a-[[[(1-methylcyclopropyl)sulfonyl]amino]carbonyl]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790302-60-2 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclobutylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,  
16,16a-hexadecahydro-2-(1-isoquinolinyloxy)-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790302-61-3 CAPLUS

CN Carbamic acid, [(2R,6S,13aR,14aR,16aS)-14a-[[[(cyclopropylsulfonyl)amino]ca  
rbonyl]octadecahydro-2-(1-isoquinolinyloxy)-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadec-6-yl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790302-63-5 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[ (cyclopropylsulfonyl) amino] carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-(1-isoquinolinyloxy)-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, methyl  
ester (9CI) (CA INDEX NAME)




RN 790302-65-7 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[ (cyclopropylsulfonyl) amino] carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-(1-isoquinolinyloxy)-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)



RN 790302-66-8 CAPLUS


CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-(1-isoquinolinyloxy)-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
tetrahydro-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)



RN 790302-67-9 CAPLUS


CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-(1-isoquinolinyloxy)-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
(3S)-tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)

10/826,743



RN 790302-68-0 CAPLUS


CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[ (cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-(1-isoquinolinyl)-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
1-methylethyl ester (9CI) (CA INDEX NAME)



RN 790302-69-1 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
acid, 6-[[ (1,1-dimethylethoxy)carbonyl]amino]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(6-methoxy-1-  
isoquinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA  
INDEX NAME)

10/826,743




RN 790302-72-6 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-(1-isoquinolinylxy)-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
cyclopentyl ester (9CI) (CA INDEX NAME)




RN 790302-73-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide,  
N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-  
tetradecahydro-2-(1-isoquinolinylxy)-6-[(2-methoxy-3,4-dioxo-1-cyclobuten-  
1-yl)amino]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX  
NAME)




RN 790302-74-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, 6-[(cyclopropylacetyl)amino]-N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(1-isoquinolinyloxy)-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 790302-76-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(1-isoquinolinyloxy)-5,16-dioxo-6-[[ (propylamino)carbonyl]amino]-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 790302-77-1 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(1-isoquinolinyloxy)-6-[(methoxyacetyl)amino]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 790302-78-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(1-isoquinolinyloxy)-6-[(methylsulfonyl)amino]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)






RN 790302-79-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, 6-(acetylamino)-N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(1-isoquinolinyloxy)-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A






RN 790302-81-7 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,6,7,8,9,11,13a,14,14a,15,16,1  
6a-tetradecahydro-2-[(6-methoxy-1-isoquinolinyl)oxy]-5,16-dioxo-5H-  
cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecin-6-yl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790302-82-8 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,6,7,8,9,11,13a,14,14a,15,  
16,16a-tetradecahydro-2-[(6-methoxy-1-isoquinolinyl)oxy]-14a-[[[(1-  
methylcyclopropyl)sulfonyl]amino]carbonyl]-5,16-dioxo-5H-  
cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecin-6-yl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790302-83-9 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(1-ethylcyclopropyl)sulfonyl]amino]carbonyl]-1,2,3,6,7,8,9,11,13a,14,14a,15,16,16a-tetradecahydro-2-[(6-methoxy-1-isoquinolinyl)oxy]-5,16-dioxo-5H-cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790302-84-0 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,6,7,8,9,11,13a,14,14a,15,16,16a-tetradecahydro-2-[(6-methoxy-1-isoquinolinyl)oxy]-5,16-dioxo-5H-cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecin-6-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 790302-85-1 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,6,7,8,9,11,13a,14,14a,15,16,1  
6a-tetradecahydro-2-[(6-methoxy-1-isoquinolinyloxy)-5,16-dioxo-5H-  
cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecin-6-yl]-,  
2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)




RN 790302-86-2 CAPLUS

CN 5H-Cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecine-14a(11H)-  
carboxamide, 6-[[[(cyclopentylamino)carbonyl]amino]-N-(cyclopropylsulfonyl)-  
1,2,3,6,7,8,9,13a,14,15,16,16a-dodecahydro-2-[(6-methoxy-1-  
isoquinolinyloxy)-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA  
INDEX NAME)



RN 790302-87-3 CAPLUS


CN 5H-Cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecine-14a(11H)-carboxamide, N-(cyclopropylsulfonyl)-6-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-1,2,3,6,7,8,9,13a,14,15,16,16a-dodecahydro-2-[(6-methoxy-1-isoquinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 790302-88-4 CAPLUS


CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,6,7,8,9,11,13a,14,14a,15,16,16a-tetradecahydro-2-[(6-methoxy-1-isoquinolinyl)oxy]-14a-[[[(1-methylcyclopropyl)sulfonyl]amino]carbonyl]-5,16-dioxo-5H-cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecin-6-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

10/826,743




RN 790302-90-8 CAPLUS

CN 5H-Cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecine-14a(11H)-carboxamide, 6-[[[(cyclopentylamino)carbonyl]amino]-1,2,3,6,7,8,9,13a,14,15,16,16a-dodecahydro-2-[(6-methoxy-1-isoquinolinyloxy)-N-[(1-methylcyclopropyl)sulfonyl]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 790302-91-9 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(1-ethylcyclopropyl)sulfonyl]amino]carbonyl]-1,2,3,6,7,8,9,11,13a,14,14a,15,16,16a-tetradecahydro-2-[(6-methoxy-1-isoquinolinyloxy)-5,16-dioxo-5H-cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecin-6-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 790302-92-0 CAPLUS

CN 5H-Cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecine-14a(11H)-carboxamide, 6-[[[(cyclopentylamino)carbonyl]amino]-N-[(1-ethylcyclopropyl)sulfonyl]-1,2,3,6,7,8,9,13a,14,15,16,16a-dodecahydro-2-[(6-methoxy-1-isoquinolinyloxy)-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 790302-93-1 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,6,7,8,9,11,13a,14,14a,15,16,16a-tetradecahydro-2-[(6-methoxy-1-isoquinolinyloxy)-5,16-dioxo-5H-cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecin-6-yl]-, 2,2,2-trifluoro-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 790302-94-2 CAPLUS


CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[ (cyclopropylsulfonyl) amino] carbonyl]-1,2,3,6,7,8,9,11,13a,14,14a,15,16,1  
 6a-tetradecahydro-2-[(6-methoxy-1-isoquinolinyl)oxy]-5,16-dioxo-5H-  
 cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecin-6-yl]-,  
 2-chloro-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 790303-04-7 CAPLUS


CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[ (cyclopropylsulfonyl) amino] carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
 ,16,16a-hexadecahydro-2-(1-isoquinolinyl oxy)-5,16-  
 dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
 1-methylcyclopentyl ester (9CI) (CA INDEX NAME)






RN 790303-05-8 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[ (cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
 ,16,16a-hexadecahydro-2-(1-isoquinolinyl)oxy)-5,16-  
 dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
 2,2,2-trifluoro-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790303-06-9 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[ (cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
 ,16,16a-hexadecahydro-2-(1-isoquinolinyl)oxy)-5,16-  
 dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
 2-chloro-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790303-08-1 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[(6-methoxy-1-isoquinolinyl)oxy]-14a-[[[(1-methylcyclopropyl)sulfonyl]amino]carbonyl]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790303-09-2 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(1-ethylcyclopropyl)sulfonyl]amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[(6-methoxy-1-isoquinolinyl)oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790303-10-5 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
 ,16,16a-hexadecahydro-2-(1-isoquinolinyloxy)-5,16-  
 dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
 2,2-difluoro-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790303-11-6 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
 ,16,16a-hexadecahydro-2-(1-isoquinolinyloxy)-5,16-  
 dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
 1-methylcyclobutyl ester (9CI) (CA INDEX NAME)




RN 790303-12-7 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-2-[(3-chloro-1-isoquinolinyl)oxy]-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790303-13-8 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-dioxo-2-[(3-phenyl-1-isoquinolinyl)oxy]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790303-14-9 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-(1-isoquinolinyloxy)-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
1-methylcyclopropyl ester (9CI) (CA INDEX NAME)




RN 790303-15-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide,  
N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-  
tetradecahydro-2-[(6-methoxy-1-isoquinolinyloxy)-5,16-dioxo-6-[(1-  
pyrrolidinylcarbonyl)amino]-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX  
NAME)




RN 790303-55-8 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[ (cyclopropylsulfonyl) amino] carbonyl]-1,2,3,6,7,8,9,11,13a,14,14a,15,16,1  
 6a-tetradecahydro-2-[(6-methoxy-3-phenyl-1-isoquinolinyl) oxy]-5,16-dioxo-  
 5H-cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecin-6-yl]-,  
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790303-56-9 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[ (cyclopropylsulfonyl) amino] carbonyl]-1,2,3,6,7,8,9,11,13a,14,14a,15,16,1  
 6a-tetradecahydro-2-[(6-methoxy-3-phenyl-1-isoquinolinyl) oxy]-5,16-dioxo-  
 5H-cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecin-6-yl]-,  
 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 790303-57-0 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[ (cyclopropylsulfonyl)amino]carbonyl]-1,2,3,6,7,8,9,11,13a,14,14a,15,16,1  
 6a-tetradecahydro-2-[(6-methoxy-3-phenyl-1-isoquinolinyl)oxy]-5,16-dioxo-  
 5H-cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecin-6-yl]-,  
 cyclopentyl ester (9CI) (CA INDEX NAME)




RN 790303-59-2 CAPLUS

CN 5H-Cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecine-14a(11H)-  
 carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,13a,14,15,16,16a-  
 dodecahydro-2-[(6-methoxy-3-phenyl-1-isoquinolinyl)oxy]-5,16-dioxo-6-[(1-  
 pyrrolidinylcarbonyl)amino]-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX  
 NAME)



RN 790303-60-5 CAPLUS


CN 5H-Cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecine-14a(11H)-carboxamide, 6-[[[(cyclopentylamino)carbonyl]amino]-N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,13a,14,15,16,16a-dodecahydro-2-[(6-methoxy-3-phenyl-1-isoquinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 790303-61-6 CAPLUS


CN 5H-Cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecine-14a(11H)-carboxamide, N-(cyclopropylsulfonyl)-6-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-1,2,3,6,7,8,9,13a,14,15,16,16a-dodecahydro-2-[(6-methoxy-3-phenyl-1-isoquinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)






RN 790303-62-7 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,6,7,8,9,11,13a,14,14a,15,16,1  
6a-tetradecahydro-2-[(6-methoxy-3-phenyl-1-isoquinolinyl)oxy]-5,16-dioxo-  
5H-cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecin-6-yl]-,  
2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)




RN 790303-63-8 CAPLUS


CN 5H-Cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecine-14a(11H)-  
carboxamide, 6-[[[(cyclopropylamino)thioxomethyl]amino]-N-  
(cyclopropylsulfonyl)-1,2,3,6,7,8,9,13a,14,15,16,16a-dodecahydro-2-[(6-  
methoxy-3-phenyl-1-isoquinolinyl)oxy]-5,16-dioxo-,  
(2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 790303-64-9 CAPLUS  
 CN 5H-Cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecine-14a(11H)-carboxamide, 6-[[[(4-cyanophenyl)amino]carbonyl]amino]-N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,13a,14,15,16,16a-dodecahydro-2-[(6-methoxy-3-phenyl-1-isoquinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 790303-65-0 CAPLUS

CN 5H-Cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecine-14a(11H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,13a,14,15,16,16a-dodecahydro-2-[(6-methoxy-3-phenyl-1-isoquinolinyl)oxy]-5,16-dioxo-6-[[2-oxo-1-imidazolidinyl)carbonyl]amino]-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI)  
(CA INDEX NAME)




RN 790303-72-9 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]-2-[[3-[4-(dimethylamino)phenyl]-6-methoxy-1-isoquinolinyl]oxy]-1,2,3,6,7,8,9,11,13a,14,14a,15,16,16a-tetradecahydro-5,16-dioxo-5H-cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)




RN 790303-73-0 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy) carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-[[6-methoxy-3-[4-(methylamino)phenyl]-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-3-hydroxy-1-propenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790303-74-1 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy) carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-[[3-[4-(formylmethylamino)phenyl]-6-methoxy-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-3-hydroxy-1-propenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790303-76-3 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(1-ethylcyclopropyl)sulfonyl]amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-(1-isoquinolinyloxy)-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790303-78-5 CAPLUS

CN Carbamothioic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-(1-isoquinolinyloxy)-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, S-ethyl ester (9CI) (CA INDEX NAME)




RN 790303-79-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-6-(formylamino)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(1-isoquinolinyloxy)-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 790303-80-9 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(1-isoquinolinyloxy)-5,16-dioxo-6-[[ (1E)-3-oxo-1-butenyl]amino]-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 790303-82-1 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
 ,16,16a-hexadecahydro-2-(1-isoquinolinyloxy)-5,16-  
 dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
 (1-methylcyclopropyl)methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


RN 790303-84-3 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
 ,16,16a-hexadecahydro-2-(1-isoquinolinyloxy)-5,16-  
 dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
 1,1-dimethyl-2-oxopropyl ester (9CI) (CA INDEX NAME)



RN 790303-85-4 CAPLUS


CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-(1-isoquinolinyloxy)-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
2,2,2-trichloro-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 790303-86-5 CAPLUS


CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-(1-isoquinolinyloxy)-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
1,1-dimethylpropyl ester (9CI) (CA INDEX NAME)






RN 790303-87-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-6-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(1-isoquinolinyloxy)-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 790303-88-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, 6-[[[(cyclopentylamino)carbonyl]amino]-N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(1-isoquinolinyloxy)-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 790303-89-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(1-isoquinolinyloxy)-6-[[[(1-methylethyl)amino]carbonyl]amino]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 790303-90-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(1-isoquinolinyloxy)-5,16-dioxo-6-[[[(1,1,3,3-tetramethylbutyl)amino]carbonyl]amino]-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 790303-91-2 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-2-[(5-chloro-1-isoquinolinyl)oxy]-14a-[[cyclopropylsulfonyl]amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790303-92-3 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-chloro-6-methoxy-1-isoquinolinyl)oxy]-14a-[[cyclopropylsulfonyl]amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790303-93-4 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-2-[(5-fluoro-6-methoxy-1-  
isoquinolinyloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-  
hexadecahydro-5,16-dioxocyclopropa[e]pyrrolo[1,2-  
a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA  
INDEX NAME)




RN 790303-95-6 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-[(5-methoxy-1-isoquinolinyloxy)-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790303-96-7 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-2-[(5,6-dimethoxy-1-  
isoquinolinyloxy]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-  
hexadecahydro-5,16-dioxocyclopropa[e]pyrrolo[1,2-  
a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA  
INDEX NAME)




RN 790303-97-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide,  
N-(cyclopropylsulfonyl)-6-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(6-methoxy-1-  
isoquinolinyloxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA  
INDEX NAME)




RN 790303-98-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, 6-[[[(cyclopentylamino)carbonyl]amino]-N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(6-methoxy-1-isoquinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 790303-99-0 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[(6-methoxy-3-phenyl-1-isoquinolinyl)oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790304-00-6 CAPLUS

CN Carbamothioic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-(1-isoquinolinyl)oxy]-5,16-  
dioxocyclopropan[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
S-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 790304-02-8 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-L-homoseryl-(4R)-  
4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-  
(cyclopropylsulfonyl)-2-[(1Z)-3-hydroxy-1-propenyl]-, cyclic  
(1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)



RN 790304-03-9 CAPLUS


CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[ (cyclopropylsulfonyl)amino]carbonyl]-2-[[3-[4-(dimethylamino)phenyl]-6-  
methoxy-1-isoquinolinyl]oxy]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-  
hexadecahydro-5,16-dioxocyclopropa[e]pyrrolo[1,2-  
a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA  
INDEX NAME)



RN 790304-05-1 CAPLUS


CN 13aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxylic  
acid, 6-[[ (1,1-dimethylethoxy)carbonyl]amino]-  
1,2,3,5,6,7,8,9,10,12a,13,14,15,15a-tetradecahydro-2-[(6-methoxy-1-  
isoquinolinyl)oxy]-5,15-dioxo-, (2R,6S,11Z,12aS,13aR,15aS)- (9CI) (CA  
INDEX NAME)






RN 790304-17-5 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-[(6-methoxy-1-isoquinolinyl)oxy]-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790304-31-3 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-[[6-methoxy-3-[4-(trifluoromethoxy)phenyl]-1-  
isoquinolinyl]oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-  
a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA  
INDEX NAME)




RN 790304-32-4 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-2-[[6-(dimethylamino)-3-[4-  
(trifluoromethoxy)phenyl]-1-isoquinolinyl]oxy]-  
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790304-33-5 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-2-[[6-(dimethylamino)-3-(4-  
methoxyphenyl)-1-isoquinolinyl]oxy]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16  
,16a-hexadecahydro-5,16-dioxocyclopropa[e]pyrrolo[1,2-  
a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA  
INDEX NAME)




RN 790304-34-6 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
 ,16,16a-hexadecahydro-2-[[6-methoxy-3-(4-morpholinyl)-1-isoquinolinyl]oxy]-  
 5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790304-35-7 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
 ,16,16a-hexadecahydro-2-[[6-methoxy-3-(1H-pyrazol-1-yl)-1-  
 isoquinolinyl]oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-  
 a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA  
 INDEX NAME)




RN 790304-36-8 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-[[6-methoxy-3-(2-oxazolyl)-1-isoquinolinyl]oxy]-  
5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 790304-37-9 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-[[6-methoxy-3-[2-[(1-methylethyl)amino]-4-  
thiazolyl]-1-isoquinolinyl]oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-  
a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA  
INDEX NAME)




RN 790304-38-0 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-2-[[3-(dimethylamino)-6-methoxy-1-  
isoquinolinyl]oxy]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-  
hexadecahydro-5,16-dioxocyclopropa[e]pyrrolo[1,2-  
a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA  
INDEX NAME)




RN 790304-39-1 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-L-homoseryl-(4R)-  
4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-  
(cyclopropylsulfonyl)-2-[(1Z)-4-hydroxy-1-butenyl]-, cyclic  
(1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790304-40-4 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy) carbonyl]-L-homoseryl-(4R)-4-[(6-methoxy-3-phenyl-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-4-hydroxy-1-butenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790304-41-5 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy) carbonyl]-L-homoseryl-(4R)-4-[[3-[4-(dimethylamino)phenyl]-6-methoxy-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-4-hydroxy-1-butenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790304-42-6 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-L-homoseryl-(4R)-4-[[6-methoxy-3-[4-(trifluoromethoxy)phenyl]-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-4-hydroxy-1-butenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790304-43-7 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-L-homoseryl-(4R)-4-[[6-(dimethylamino)-3-[4-(trifluoromethoxy)phenyl]-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-4-hydroxy-1-butenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)



RN 790304-44-8 CAPLUS


CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-L-homoseryl-(4R)-4-[[6-(dimethylamino)-3-(4-methoxyphenyl)-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-4-hydroxy-1-butenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)



RN 790304-45-9 CAPLUS


CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-L-homoseryl-(4R)-4-(1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-4-hydroxy-1-butenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)






RN 790304-46-0 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-L-homoseryl-(4R)-4-[[6-methoxy-3-(4-morpholinyl)-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-4-hydroxy-1-butenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790304-47-1 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-L-homoseryl-(4R)-4-[[6-methoxy-3-(1H-pyrazol-1-yl)-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-4-hydroxy-1-butenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790304-48-2 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-L-homoseryl-(4R)-4-[[6-methoxy-3-(2-oxazolyl)-1-isoquinolinyloxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-4-hydroxy-1-butenyl]-, cyclic (1-3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790304-49-3 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-L-homoseryl-(4R)-4-[[6-methoxy-3-[2-[(1-methylethyl)amino]-4-thiazolyl]-1-isoquinolinyloxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-4-hydroxy-1-butenyl]-, cyclic (1-3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790304-50-6 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-L-homoseryl-(4R)-4-[[3-(dimethylamino)-6-methoxy-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-4-hydroxy-1-butenyl]-, cyclic (1+3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790304-72-2 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-[[6-methoxy-3-[4-(trifluoromethoxy)phenyl]-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-3-hydroxy-1-propenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790304-73-3 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-[[[6-(dimethylamino)-3-[4-(trifluoromethoxy)phenyl]-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-3-hydroxy-1-propenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790304-74-4 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-[[[6-(dimethylamino)-3-(4-methoxyphenyl)-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-3-hydroxy-1-propenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790304-75-5 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-(1-isoquinolininyloxy)-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-3-hydroxy-1-propenyl]-, cyclic (1-3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790304-76-6 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-[[6-methoxy-3-(4-morpholinyl)-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-3-hydroxy-1-propenyl]-, cyclic (1-3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790304-77-7 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-[[6-methoxy-3-(1H-pyrazol-1-yl)-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-3-hydroxy-1-propenyl]-, cyclic (1-3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790304-78-8 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-[[6-methoxy-3-(2-oxazolyl)-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-3-hydroxy-1-propenyl]-, cyclic (1-3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




RN 790304-79-9 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-[[6-methoxy-3-[2-[(1-methylethyl)amino]-4-thiazolyl]-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-3-hydroxy-1-propenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)



RN 790304-81-3 CAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-[[3-(dimethylamino)-6-methoxy-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-[(1Z)-3-hydroxy-1-propenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




IT 790304-88-0P 790304-98-2P 790305-10-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of macrocyclic isoquinoline peptide inhibitors of hepatitis C virus)

RN 790304-88-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(1-isoquinolinyl)oxy]-5,16-dioxo-, ethyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 790304-98-2 CAPLUS

CN Cyclopropanecarboxylic acid, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-2-[(1Z)-3-hydroxy-1-propenyl]-, ethyl ester, cyclic (1→3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)




10/826,743



RN 790305-10-1 CAPLUS

CN Cyclopropanecarboxylic acid, N-[(1,1-dimethylethoxy)carbonyl]-L-homoseryl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-2-[(1Z)-3-hydroxy-1-propenyl]-, ethyl ester, cyclic (1-3)-ether, (1R,2S)- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:927080 CAPLUS

DN 141:400901

TI Pharmaceutical compositions for hepatitis C viral protease inhibitors

IN Chen, Shirlynn; Mei, Xiaohui; Wang, Zeren

PA Boehringer Ingelheim International, G.m.b.H., Germany

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004093915	A1	20041104	WO 2004-US8837	20040323
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2004229776 A1 20041118 US 2004-807023 20040323

PRAI US 2003-459765P P 20030402

OS MARPAT 141:400901

AB Disclosed are pharmaceutical compns. of hepatitis C viral protease inhibitors, and methods of using these compns. for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. These compns. are lipid based systems and comprise the hepatitis C viral protease inhibitor together with at least one pharmaceutically acceptable amine, at least one pharmaceutically acceptable base, at least one pharmaceutically acceptable oil and optionally one or more addnl. ingredients. For example, a formulation was prepared containing hepatitis C protease inhibitor 10, tromethamine 1, sodium hydroxide 0.3, water 1.7, ethanol 10, propylene glycol 5,  $\alpha$ -tocopherol 0.4, Capmul MCM 22, and TPGS 49.6%, resp. The formulation can be filled into hard shell or soft gelatin capsules.

IT 300832-64-8 300832-66-0 300832-67-1

300832-69-3 300832-70-6 300832-71-7

300832-72-8 300832-73-9 300832-74-0

300832-76-2 300832-77-3 300832-78-4

300832-79-5 300832-80-8 300832-81-9

300832-83-1 300832-84-2 300832-85-3

300832-86-4 572922-86-2 572922-94-2

577965-78-7 577965-82-3 577965-83-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral compns. for hepatitis C viral protease inhibitors)


RN 300832-64-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclobutyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





PAGE 2-B



RN 300832-66-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[[[(1R)-1,2,2-trimethylpropyl]amino]carbonyl]amino]-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 300832-67-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1H-pyrrol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 300832-69-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 300832-70-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[[(1-methylethoxy)carbonyl]amino]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



10/826,743


RN 300832-71-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



10/826,743


RN 300832-72-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B





10/826,743


RN 300832-73-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentyloxy) carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-(methylamino)-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



10/826,743


RN 300832-74-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(2-amino-4-thiazolyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



10/826,743


RN 300832-76-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(2-thiazolyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



10/826,743


RN 300832-77-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(6-methyl-2-pyridinyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.


Double bond geometry as shown.

PAGE 1-A



PAGE 1-B







RN 300832-78-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[[[(1R)-1,2,2-trimethylpropyl]amino]carbonyl]amino]-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 300832-79-5 CAPLUS

10/826,743


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 300832-80-8 CAPLUS

10/826,743


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(methoxycarbonyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 300832-81-9 CAPLUS

10/826,743


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[[2-[[[(2-methylpropoxy)carbonyl]amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



RN 300832-83-1 CAPLUS




10/826,743


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



RN 300832-84-2 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic

10/826,743


acid, 6-[[ (cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[[2-[(1-methylethyl) amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 300832-85-3 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic

10/826,743


acid, 6-[[[(cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-(3-methyl-1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B



RN 300832-86-4 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic

10/826,743

acid, 6-[[ (cyclopentyloxy) carbonyl] amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl) oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-9-methyl-5,16-dioxo-, (2R,6S,9R,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)






RN 572922-86-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclopentylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[ (cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A








RN 572922-94-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclohexylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyl)oxy]carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.







RN 577965-78-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclobutyloxy)carbonyl]amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 577965-82-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-[2-(cyclopropylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 577965-83-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclobutylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.







RE.CNT 3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:905774 CAPLUS  
 DN 141:380136  
 TI Process for preparing macrocyclic compounds  
 IN Donsbach, Kai; Ecker, Dieter; Frutos, Rogelio Perez; Gallou, Fabrice;  
 Gutheil, Dieter; Haddad, Nizar; Hagenkoetter, Robert; Kemmer, Dirk;  
 Kroeber, Jutta; Nicola, Thomas; Schnaubelt, Juergen; Schul, Michael;  
 Simpson, Robert Donald; Wei, Xudong; Winter, Eric; Xu, Yibo; Yee, Nathan  
 K.; Brandenburg, Joerg  
 PA Boehringer Ingelheim International, G.m.b.H., Germany; Boehringer  
 Ingelheim Pharma G.m.b.H. & Co. K.-G.  
 SO PCT Int. Appl., 59 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004092203	A2	20041028	WO 2004-US10476	20040406
	WO 2004092203	A3	20041209		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,				
	SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,				
	TD, TG				
	US 2005049187	A1	20050303	US 2004-818657	20040406
PRAI	US 2003-461662P	P	20030410		
OS	MARPAT 141:380136				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Disclosed is a process for preparing macrocyclic compds. I [W is CH or N; R1  
 is H, halo, alkyl, cycloalkyl, haloalkyl, alkoxy, cycloalkoxy, hydroxy or  
 an amino group; R2 is H, halo, alkyl, haloalkyl, thioalkyl, alkoxy,  
 cycloalkoxy, alkoxyalkyl, (un)substituted cycloalkyl, aryl or  
 heterocyclyl; R3 is OH, NH2, aryl-, heteroaryl- or acylamino; D is  
 alkylene which may be substituted by R4 (alkyl, alkoxy, halo, amino,  
 etc.); A is CO2H or an amide or salt] which are potent active agents for  
 the treatment of hepatitis C virus (HCV) infection. The process involves  
 reaction of a 4-hydroxyproline sulfonate macrocycle with a 4-naphthol or  
 4-quinolinol derivative and was applied to the synthesis of II by a multistep  
 sequence.

IT **681145-22-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(process for preparing macrocyclic compds.)

RN 681145-22-2 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
 acid, 6-[[[(cyclopentylloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16  
 ,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-  
 4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-

10/826,743


(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



IT 300832-64-8P 300832-65-9P 300832-66-0P  
300832-67-1P 300832-69-3P 300832-71-7P  
300832-72-8P 300832-73-9P 300832-74-0P  
300832-76-2P 300832-77-3P 300832-78-4P  
300832-79-5P 300832-80-8P 300832-81-9P

10/826,743

300832-83-1P 300832-84-2P 300832-85-3P

300832-86-4P 572922-86-2P 572922-94-2P

577965-78-7P 577965-82-3P 577965-83-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(process for preparing macrocyclic compds.)


RN 300832-64-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclobutyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.


Double bond geometry as shown.

PAGE 1-A




PAGE 1-B







RN 300832-65-9 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[(2-methyl-1-oxopropyl)amino]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-66-0 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[[[(1R)-1,2,2-trimethylpropyl]amino]carbonyl]amino]-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.








RN 300832-67-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-(1H-pyrrol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.







RN 300832-69-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 300832-71-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.










RN 300832-72-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.







RN 300832-73-9 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-(methylamino)-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.








RN 300832-74-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(2-amino-4-thiazolyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 300832-76-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(2-thiazolyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 300832-77-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(6-methyl-2-pyridinyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.







RN 300832-78-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[[[(1R)-1,2,2-trimethylpropyl]amino]carbonyl]amino]-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 300832-79-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 300832-80-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-[2-[(methoxycarbonyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.










RN 300832-81-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[[ (2-methylpropoxy) carbonyl] amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 300832-83-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 300832-84-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.








RN 300832-85-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(3-methyl-1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.





RN 300832-86-4 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-9-methyl-5,16-dioxo-, (2R,6S,9R,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743






RN 572922-86-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclopentylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentylamino)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A








RN 572922-94-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclohexylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.







RN 577965-78-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclobutyloxy)carbonyl]amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.










RN 577965-82-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-[2-(cyclopropylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 577965-83-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclobutylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.






10/826,743

L5 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:857622 CAPLUS  
DN 141:337786  
TI Crystalline phases of a potent HCV inhibitor  
IN Cerreta, Michael Kenneth; Smoliga, John Andrew; Varsolona, Richard J.  
PA Boehringer Ingelheim International GmbH, Germany  
SO PCT Int. Appl., 43 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004087741	A1	20041014	WO 2004-US9085	20040325
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004229777	A1	20041118	US 2004-809597	20040325
PRAI	US 2003-458188P	P	20030327		
GI					



I

AB This invention relates to novel crystalline phases of Compound (I), methods for the preparation thereof, pharmaceutical compns. thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection.

IT **300832-84-2P**  
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PNU (Preparation, unclassified); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
(crystalline phases of a potent HCV inhibitor)


10/826,743

RN 300832-84-2 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



10/826,743

RE.CNT 3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:846584 CAPLUS

DN 142:147589

TI Past, present, and future hepatitis C treatments

AU Foster, Graham R.

CS Hepatobiliary Group, Department of Adult and Paediatric Gastroenterology, Queen Marys School of Medicine and Dentistry, London, UK

SO Seminars in Liver Disease (2004), 24(Suppl. 2), 97-104

CODEN: SLDIEE; ISSN: 0272-8087

PB Thieme Medical Publishers, Inc.

DT Journal; General Review

LA English

AB A review. Conventional interferon (IFN) alfa has been used for many years in the treatment of chronic hepatitis C. However, few patients achieve sustained virological responses with IFN. Combining IFN with ribavirin improves efficacy considerably, but at the expense of diminished tolerability attributable to ribavirin. Pegylated interferons have improved pharmacokinetic profiles, may be administered once weekly, and are more effective than IFN is alone or in combination with ribavirin. In addition to enhanced efficacy, pegylated interferon alfa-2a (40 kD) also improves health-related quality of life during therapy compared with IFN-based therapy. New adjuvant agents have the potential to further improve sustained response rates and tolerability; however, pegylated interferons will likely remain the backbone of therapy in the foreseeable future. Therapies under development and evaluation for patients with HCV infection include adjunctive use of the antiviral agent amantadine and the immunomodulatory agent thymalfasin. Novel small molecules include the ribavirin analogs, viramidine and levovirin, and BILN 2061, an inhibitor of HCV serine protease. Other therapeutic strategies that have reached the clinic include antisense oligonucleotides (ISIS 14803), nuclease-resistant ribozymes targeting HCV RNA (Heptazyme), human monoclonal antibodies, and human antibody fragments directed at HCV helicase.

IT 300832-84-2, BILN 2061

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(past, present, and future hepatitis C treatments)


RN 300832-84-2 CAPLUS



CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A





RE.CNT 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L5 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:654859 CAPLUS

DN 141:332465

TI Potent Inhibitors of the Hepatitis C Virus NS3 Protease: Design and Synthesis of Macrocyclic Substrate-Based  $\beta$ -Strand Mimics

AU Goudreau, Nathalie; Brochu, Christian; Cameron, Dale R.; Duceppe, Jean-Simon; Faucher, Anne-Marie; Ferland, Jean-Marie; Grand-Maitre, Chantal; Poirier, Martin; Simoneau, Bruno; Tsantrizos, Youla S.

CS Departments of Chemistry, Research and Development, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2G5, Can.

SO Journal of Organic Chemistry (2004), 69(19), 6185-6201  
CODEN: JOCEAH; ISSN: 0022-3263

PB American Chemical Society

DT Journal

LA English

AB The virally encoded NS3 protease is essential to the life cycle of the hepatitis C virus (HCV), an important human pathogen causing chronic hepatitis, cirrhosis of the liver, and hepatocellular carcinoma. The design and synthesis of 15-membered ring  $\beta$ -strand mimics which are capable of inhibiting the interactions between the HCV NS3 protease enzyme and its polyprotein substrate will be described. The binding interactions between a macrocyclic ligand and the enzyme were explored by NMR and mol. dynamics, and a model of the ligand/enzyme complex was developed.


IT **300831-83-8P 770742-77-3P**

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and biol. activity of macrocyclic substrate-based  $\beta$ -strand mimics as potent inhibitors of HCV NS3 protease)

RN 300831-83-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 770742-77-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-(acetamino)-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(4-quinolinyl)oxy-, (2R,6S,10E,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B




IT 300831-89-4P 300832-02-4P 300832-03-5P  
 770742-63-7P 770742-76-2P 770742-81-9P  
 770742-84-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
 (Biological study); PREP (Preparation)  
 (preparation and biol. activity of macrocyclic substrate-based  $\beta$ -strand  
 mimics as potent inhibitors of HCV NS3 protease)

RN 300831-89-4 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
 acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-  
 phenyl-4-quinolinyloxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA  
 INDEX NAME)

10/826,743



RN 300832-02-4 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,10E,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-03-5 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,10Z,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743




RN 770742-63-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(4-quinolinyloxy)-, (2R,6S,10E,13aS,14aS,16aS)- (9CI) (CA INDEX NAME)



RN 770742-76-2 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(4-quinolinyloxy)-, (2R,6S,10E,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)



10/826,743


RN 770742-81-9 CAPLUS

CN 1H-Pyrrolo[1,2-a][1,4]diazacyclopentadecane-3-carboxylic acid,  
12-[[[(1,1-dimethylethoxy) carbonyl] amino]hexadecahydro-16-[(7-methoxy-2-  
phenyl-4-quinolinyl)oxy]-1,13-dioxo-, (3R,12S,16R,17aS)- (9CI) (CA INDEX  
NAME)



RN 770742-84-2 CAPLUS

CN 1H-Pyrrolo[1,2-a][1,4]diazacyclopentadecane-3-carboxylic acid,  
12-[[[(1,1-dimethylethoxy) carbonyl] amino]hexadecahydro-16-[(7-methoxy-2-  
phenyl-4-quinolinyl)oxy]-1,13-dioxo-, (3S,12S,16R,17aS)- (9CI) (CA INDEX  
NAME)



IT 300831-63-4P 770742-75-1P 770742-79-5P

770742-80-8P 770742-82-0P 770742-83-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)


(preparation and biol. activity of macrocyclic substrate-based  $\beta$ -strand  
mimics as potent inhibitors of HCV NS3 protease)

RN 300831-63-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-  
4-quinolinyl)oxy]-5,16-dioxo-, ethyl ester, (2R,6S,12Z,13aS,14aR,16aS)-


10/826,743

(9CI) (CA INDEX NAME)




RN 770742-75-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(4-quinolinyl)oxy]-, methyl ester, (2R,6S,10E,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 770742-79-5 CAPLUS

CN 1H-Pyrrolo[1,2-a][1,4]diazacyclopentadecine-3-carboxylic acid, 12-[[[(1,1-dimethylethoxy)carbonyl]amino]-2,3,4,7,8,9,10,11,12,13,15,16,17,17a-tetradecahydro-16-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-1,13-dioxo-, methyl ester, (3R,12S,16R,17aS)- (9CI) (CA INDEX NAME)




RN 770742-80-8 CAPLUS

CN 1H-Pyrrolo[1,2-a][1,4]diazacyclopentadecane-3-carboxylic acid,  
12-[[ (1,1-dimethylethoxy) carbonyl] amino]hexadecahydro-16-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-1,13-dioxo-, methyl ester, (3R,12S,16R,17aS)-  
(9CI) (CA INDEX NAME)




RN 770742-82-0 CAPLUS

CN 1H-Pyrrolo[1,2-a][1,4]diazacyclopentadecine-3-carboxylic acid,  
12-[[ (1,1-dimethylethoxy) carbonyl] amino]-2,3,4,7,8,9,10,11,12,13,15,16,17,  
17a-tetradecahydro-16-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-1,13-dioxo-,  
methyl ester, (3S,5E,12S,16R,17aS)- (9CI) (CA INDEX NAME)



RN 770742-83-1 CAPLUS

CN 1H-Pyrrolo[1,2-a][1,4]diazacyclopentadecane-3-carboxylic acid,  
12-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-16-[(7-methoxy-2-  
phenyl-4-quinolinyl)oxy]-1,13-dioxo-, methyl ester, (3S,12S,16R,17aS)-  
(9CI) (CA INDEX NAME)



RE.CNT 100 THERE ARE 100 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L5 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:590266 CAPLUS

DN 141:184653

TI Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061

AU Thibeault, Diane; Bousquet, Christiane; Gingras, Rock; Lagace, Lisette; Maurice, Roger; White, Peter W.; Lamarre, Daniel

CS Department of Biological Sciences, Research and Development, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2G5, Can.

SO Journal of Virology (2004), 78(14), 7352-7359

CODEN: JOVIAM; ISSN: 0022-538X

PB American Society for Microbiology

DT Journal

LA English

AB Hepatitis C virus (HCV) displays a high degree of genetic variability. Six genotypes and more than 50 subtypes have been identified to date. In this report, kinetic profiles were determined for NS3 proteases of genotypes 1a, 1b, 2ac, 2b, and 3a, revealing no major differences in activity. In vitro sensitivity studies with BILN 2061 showed a decrease in affinity for proteases of genotypes 2 and 3 ( $K_i$ , 80 to 90 nM) compared to genotype 1 enzymes ( $K_i$ , 1.5 nM). To understand the reduced sensitivity of genotypes 2 and 3 to BILN 2061, active-site residues in the proximity of the inhibitor binding site were replaced in the genotype-1b enzyme with the corresponding genotype-2b or -3a residues. The replacement of five residues at positions 78, 79, 80, 122, and 132 accounted for most of the reduced sensitivity of genotype 2b, while replacement of residue 168 alone could account for the reduced sensitivity of genotype 3a. BILN 2061 remains a potent inhibitor of these non-genotype-1 NS3-NS4A proteins, with  $K_i$  values below 100 nM. This in vitro potency, in conjunction with the good pharmacokinetic data reported for humans, suggests that there is potential for BILN 2061 as an antiviral agent for individuals infected with non-genotype-1 HCV.

IT 300832-84-2, BILN 2061

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(HCV genotypes 2 and 3 NS3 serine proteases sensitive to inhibitor BILN 2061)


RN 300832-84-2 CAPLUS



CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A





RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:580783 CAPLUS  
 DN 141:261053  
 TI Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans  
 AU Faucher, Anne-Marie; Bailey, Murray D.; Beaulieu, Pierre L.; Brochu, Christian; Duceppe, Jean-Simon; Ferland, Jean-Marie; Ghio, Elise; Gorys, Vida; Halmos, Ted; Kawai, Stephen H.; Poirier, Martin; Simoneau, Bruno; Tsantrizos, Youla S.; Llinas-Brunet, Montse  
 CS Chemistry Department, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2G5, Can.  
 SO Organic Letters (2004), 6(17), 2901-2904  
 CODEN: ORLEF7; ISSN: 1523-7060  
 PB American Chemical Society  
 DT Journal  
 LA English  
 GI




AB The synthesis of BILN 2061 (I), a hepatitis C virus (HCV) NS3 protease inhibitor with proven antiviral effect in humans, was accomplished in a convergent manner from four building blocks. The procedure described here was suitable for the preparation of multigram quantities of BILN 2061 for preclin. pharmacol. evaluation.  
 IT **300832-84-2P**  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of peptidyl macrocycle BILN-2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans)  
 RN 300832-84-2 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



IT 300831-72-5P 300831-74-7P 681145-22-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of peptidyl macrocycle BILN-2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans)

RN 300831-72-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-

10/826,743

(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester,  
(2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)






RN 300831-74-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A








RN 681145-22-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.





RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:468978 CAPLUS

DN 141:220806

TI Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

AU Lu, Liangjun; Pilot-Matias, Tami J.; Stewart, Kent D.; Randolph, John T.; Pithawalla, Ron; He, Wenping; Huang, Peggy P.; Klein, Larry L.; Mo, Hongmei; Molla, Akhteruzzaman

CS Antiviral Research, Global Pharmaceutical Research and Development, Abbott Park, IL, USA

SO Antimicrobial Agents and Chemotherapy (2004), 48(6), 2260-2266  
CODEN: AMACCQ; ISSN: 0066-4804

PB American Society for Microbiology

DT Journal

LA English

AB BILN 2061 is a novel, specific hepatitis C virus (HCV) NS3 serine protease inhibitor discovered by Boehringer Ingelheim that has shown potent activity against HCV replicons in tissue culture and is currently under clin. investigation for the treatment of HCV infection. The poor fidelity of the HCV RNA-dependent RNA polymerase will likely lead to the development of drug-resistant viruses in treated patients. The development of resistance to BILN 2061 was studied by the in vitro passage of HCV genotype 1b replicon cells in the presence of a fixed concentration of

the

drug. Three weeks posttreatment, four colonies were expanded for genotypic and phenotypic characterization. The 50% inhibitory concns. of BILN 2061 for these colonies were 72- to 1228-fold higher than that for the wild-type replicon. Sequencing of the individual colonies identified several mutations in the NS3 serine protease gene. Mol. clones containing the single amino acid substitution A156T, R155Q, or D168V resulted in 357-fold, 24-fold, and 144-fold redns. in susceptibility to BILN 2061, resp., compared to the level of susceptibility shown by the wild-type replicon. Modeling studies indicate that all three of these residues are located in close proximity to the inhibitor binding site. These findings, in addition to the three-dimensional structure anal. of the NS3/NS4A serine protease inhibitor complex, provide a strategic guide for the development of next-generation inhibitors of HCV NS3/NS4A serine protease.

IT 300832-84-2, BILN 2061

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(mutations conferring inhibitor resistance on hepatitis C virus serine protease)

RN 300832-84-2 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.




PAGE 1-A



PAGE 1-B



PAGE 2-B



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:392478 CAPLUS

DN 140:400031

TI Macrocyclic compound-containing compositions for the treatment of infection by Flaviviridae viruses

IN Lamarre, Daniel; Lagace, Lisette

PA Boehringer Ingelheim International GmbH, Germany

SO PCT Int. Appl., 57 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004039833	A1	20040513	WO 2003-CA1634	20031024
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-421900P	P	20021029		
	US 2003-442769P	P	20030127		
OS	MARPAT 140:400031				
GI					




AB The invention relates to macrocyclic compds. I [A is alkyl or cycloalkyl; B is Ph or thiazolyl, which may be substituted by alkylamino or alkanoylamino; R is OH or NHSO<sub>2</sub>R<sub>2</sub>, where R<sub>2</sub> is (un)substituted alkyl, cycloalkyl or aryl] or their pharmaceutically-acceptable salts for the treatment of a mammal infected with a virus of the Flaviviridae family. Thus, IC<sub>50</sub> values for compound I [A is cyclopentyl, B is 2-(isopropylamino)-4-thiazolyl, R is OH] against HCV NS3-NS4A protease are shown graphically.

IT 300831-83-8 300832-25-1 300832-84-2


552335-24-7 681145-23-3 681145-24-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)(macrocyclic compound-containing compns. for treatment of infection by  
Flaviviridae viruses)

RN 300831-83-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-  
4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA  
INDEX NAME)

RN 300832-25-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
acid, 2-[[2-[2-(acetamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-  
[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-  
tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX  
NAME)

RN 300832-84-2 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,  
16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-  
4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.


10/826,743

Double bond geometry as shown.


PAGE 1-A




PAGE 1-B



PAGE 2-B



RN 552335-24-7 CAPLUS  
CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-  
thiazolyl]-4-quinolinyl]oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-  
a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX  
NAME)






RN 681145-23-3 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-14a-[[[(methylsulfonyl)amino]carbonyl]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A








RN 681145-24-4 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-14a-[(phenylsulfonyl)amino]carbonyl]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.






RE.CNT 8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/826,743

L5 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:370958 CAPLUS  
DN 140:357673  
TI Preparation of macrocyclic peptides active against the hepatitis C virus  
IN Llinas-Brunet, Montse; Bailey, Murray D.  
PA Boehringer Ingelheim International G.m.b.h., Germany  
SO PCT Int. Appl., 40 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037855	A1	20040506	WO 2003-CA1604	20031020
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005075279	A1	20050407	US 2003-686755	20031016
PRAI	US 2002-421414P	P	20021025		
	US 2002-433820P	P	20021216		
	US 2003-442768P	P	20030127		
OS	MARPAT 140:357673				
GI					



I

AB Macrocyclic peptides I [R1 is (un)substituted alkyl, cycloalkyl, alkylcycloalkyl, aryl or heteroaryl] or their pharmaceutically-acceptable salts were prepared as inhibitors of the hepatitis C virus (HCV) NS3



protease. Thus, I (R = Me) was prepared by a multistep sequence involving peptide coupling, olefin metathesis to form the macrocycle and methanesulfonamidation.


IT 552335-24-7P 681145-23-3P 681145-24-4P  
681145-25-5P 681145-26-6P 681145-27-7P  
681145-28-8P 681145-29-9P 681145-30-2P  
681145-32-4P 681145-33-5P 681145-34-6P  
681145-35-7P 681145-36-8P 681145-37-9P  
681145-38-0P 681145-39-1P 681145-40-4P  
681145-41-5P 681145-42-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocyclic peptides active against the hepatitis C virus)

RN 552335-24-7 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 681145-23-3 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-14a-[[[(methylsulfonyl)amino]carbonyl]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 681145-24-4 CAPLUS  
 CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-14a-[[ (phenylsulfonyl)amino]carbonyl]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 681145-25-5 CAPLUS  
 CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-14a-[[4-morpholinylsulfonyl]amino]carbonyl]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 681145-26-6 CAPLUS  
 CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-14a-[[[(4-methyl-1-piperazinyl)sulfonyl]amino]carbonyl]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)


10/826,743

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 681145-27-7 CAPLUS  
CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-14a-[(2-

10/826,743


pyridinylsulfonyl)amino]carbonyl]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




10/826,743


CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-14a-[[[3-pyridinylsulfonyl)amino]carbonyl]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B







RN 681145-29-9 CAPLUS  
 CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-14a-[[4-pyridinylsulfonyl)amino]carbonyl]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.  
 Double bond geometry as shown.










RN 681145-30-2 CAPLUS  
 CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-14a-[[2-thiazolylsulfonyl]amino]carbonyl]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)



RN 681145-32-4 CAPLUS  
 CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[(ethylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16  
 a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-  
 quinolinyl]oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-  
 a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.








RN 681145-33-5 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-14a-[(propylsulfonyl)amino]carbonyl]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 681145-34-6 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-14a-[[[(1-methylethyl)sulfonyl]amino]carbonyl]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.







RN 681145-35-7 CAPLUS  
 CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[[(cyclobutylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,  
 16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-  
 thiazolyl]-4-quinolinyl]oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-  
 a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A





PAGE 1-B



PAGE 2-B






RN 681145-36-8 CAPLUS  
 CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[[(cyclopentylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
 ,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-  
 thiazolyl]-4-quinolinyl]oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-  
 a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX  
 NAME)



RN 681145-37-9 CAPLUS  
 CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[[ (cyclopropylmethyl)sulfonyl]amino]carbonyl]-  
 1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-  
 [2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-  
 dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
 cyclopentyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.  
 Double bond geometry as shown.





RN 681145-38-0 CAPLUS  
 CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(2-cyclohexylethyl)sulfonyl]amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)








RN 681145-39-1 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-14a-[[[(trichloromethyl)sulfonyl]amino]carbonyl]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 681145-40-4 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-14a-[[[(trifluoromethyl)sulfonyl]amino]carbonyl]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 681145-41-5 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(2-fluorophenyl)sulfonyl]amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 681145-42-6 CAPLUS  
 CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-14a-[[[(4-methylphenyl)sulfonyl]amino]carbonyl

10/826,743


1]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



IT 300831-72-5P 300831-74-7P 300831-75-8P  
300831-76-9P 300831-77-0P 300832-84-2P


**681145-22-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of macrocyclic peptides active against the hepatitis C virus)

RN 300831-72-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 300831-74-7 CAPLUS



CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A






RN 300831-75-8 CAPLUS  
 CN Cyclopropa[el]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-carboxy-7-methoxy-4-quinolinyl)oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, 14a-methyl ester, monosodium salt, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.






● Na



RN 300831-76-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-(diazooacetyl)-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.










RN 300831-77-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(bromoacetyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 300832-84-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl) amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 681145-22-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.





L5 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:325457 CAPLUS

DN 141:16899

TI In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

AU Lin, Chao; Lin, Kai; Luong, Yu-Ping; Rao, B. Govinda; Wei, Yun-Yi; Brennan, Debra L.; Fulghum, John R.; Hsiao, Hsun-Mei; Ma, Sue; Maxwell, John P.; Cottrell, Kevin M.; Perni, Robert B.; Gates, Cynthia A.; Kwong, Ann D.

CS Vertex Pharmaceuticals Inc., Cambridge, MA, 02139, USA

SO Journal of Biological Chemistry (2004), 279(17), 17508-17514  
CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

AB We have used a structure-based drug design approach to identify small mol. inhibitors of the hepatitis C virus (HCV) NS3-4A protease as potential candidates for new anti-HCV therapies. VX-950 is a potent NS3-4A protease inhibitor that was recently selected as a clin. development candidate for hepatitis C treatment. In this report, we describe in vitro resistance studies using a subgenomic replicon system to compare VX-950 with another HCV NS3-4A protease inhibitor, BILN 2061, for which the Phase I clin. trial results were reported recently. Distinct drug-resistant substitutions of a single amino acid were identified in the HCV NS3 serine protease domain for both inhibitors. The resistance conferred by these mutations was confirmed by characterization of the mutant enzymes and replicon cells that contain the single amino acid substitutions. The major BILN 2061-resistant mutations at Asp168 are fully susceptible to VX-950, and the dominant resistant mutation against VX-950 at Ala156 remains sensitive to BILN 2061. Modeling anal. suggests that there are different mechanisms of resistance to VX-950 and BILN 2061.

IT 300832-84-2, BILN 2061

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(structure-activity relationship and in vitro antiviral resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061)


RN 300832-84-2 CAPLUS



CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A





RE.CNT. 40


THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/826,743

L5 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:310970 CAPLUS  
DN 140:327091  
TI Potent inhibitor of HCV serine protease  
IN Chen, Shirlynn; Nehmiz, Gerhard; Croenlein, Jens Oliver; Steinmann,  
Gerhard; Gunn, Jocelyn Abella; Costa, Phuong Do  
PA Boehringer Ingelheim International G.m.b.H., Germany  
SO PCT Int. Appl., 42 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004030670	A1	20040415	WO 2003-US30402	20030925
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004138109	A1	20040715	US 2003-663220	20030916
PRAI	US 2002-414940P	P	20020930		
	US 2002-421904P	P	20021029		
	US 2002-433834P	P	20021216		
	US 2003-443662P	P	20030130		

GI



AB Disclosed are oral pharmaceutical compns., kits and methods of treating and preventing Hepatitis C Viral (HCV) infections wherein Compound (I), a potent inhibitor of HCV serine protease, or a pharmaceutically acceptable salt thereof, is administered in a selected dosage range. Also disclosed are the use of I or a pharmaceutically acceptable salt thereof, as a control substance for validating an HCV replication assay and also as a control substance for determining the relative effectiveness of one or more substances, alone or in combination, to inhibit the replication of HCV.

IT **300832-84-2**

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)


(potent inhibitor of HCV serine protease)

RN 300832-84-2 CAPLUS



CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A








RE.CNT 3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/826,743

L5 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:252197 CAPLUS  
DN 140:281350  
TI Spiro compounds for inhibiting the first-pass effect  
IN Harris, James W.  
PA Bioavailability System, LLC, USA  
SO U.S. Pat. Appl. Publ., 133 pp., Cont.-in-part of U.S. Ser. No. 793,416.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004058982	A1	20040325	US 2003-422848	20030425
	US 6248776	B1	20010619	US 1999-251467	19990217
	US 6476066	B1	20021105	US 2001-793416	20010227
PRAI	US 1999-251467	A3	19990217		
	US 2001-793416	A2	20010227		
	US 1997-56382P	P	19970826		
	US 1997-997259	A2	19971223		
OS	MARPAT 140:281350				
GI					



AB Compns., methods, etc. for addressing the first-pass effect are presented. An example compound prepared was I. Also processing citrus oils to obtain the compds. is given as examples as well as assessment of human cytochrome P 450-mediated biotransformation.


IT **300832-84-2**, BILN 2061  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(spiro compds. for inhibiting the first-pass effect)

RN 300832-84-2 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



L5 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:168624 CAPLUS

DN 140:350045

TI Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061

AU Llinas-Brunet, Montse; Bailey, Murray D.; Bolger, Gordon; Brochu, Christian; Faucher, Anne-Marie; Ferland, Jean Marie; Garneau, Michel; Ghiro, Elise; Gorys, Vida; Grand-Maitre, Chantal; Halmos, Ted; Lapeyre-Paquette, Nicole; Liard, Francine; Poirier, Martin; Rheaume, Manon; Tsantrizos, Youla S.; Lamarre, Daniel

CS Departments of Chemistry and Biological Sciences, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2G5, Can.

SO Journal of Medicinal Chemistry (2004), 47(7), 1605-1608

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB From the discovery of competitive hexapeptide inhibitors, potent and selective HCV NS3 protease macrocyclic inhibitors have been identified. Structure-activity relationship studies were performed focusing on optimizing the N-terminal carbamate and the aromatic substituent on the (4R)-hydroxyproline moiety. Inhibitors meeting the potency criteria in the cell-based assay and with improved oral bioavailability in rats were identified. BILN 2061 was selected as the best compound, the first NS3 protease inhibitor reported with antiviral activity in man.

IT 300832-84-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(BILN 2061; structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061)


RN 300832-84-2 CAPLUS



CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A





## IT 300832-73-9P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061)

RN 300832-73-9 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-[2-(methylamino)-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




IT 300831-82-7P 300831-83-8P 300832-25-1P  
 300832-37-5P 300832-38-6P 300832-40-0P  
 300832-44-4P 300832-51-3P 300832-53-5P  
 300832-55-7P 300832-56-8P 300832-60-4P  
 300832-64-8P 300832-66-0P 300832-67-1P  
 300832-71-7P 300832-72-8P 300832-74-0P  
 300832-83-1P 300832-85-3P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061)


RN 300831-82-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300831-83-8 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-25-1 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[[2-[2-(acetamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743



RN 300832-37-5 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1H-pyrrol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300832-38-6 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)






RN 300832-40-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[2-(1H-imidazol-1-yl)-7-methoxy-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME).




RN 300832-44-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(4-methyl-1H-imidazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 300832-51-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-[(methylamino)-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-53-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[[2-(2-amino-4-thiazolyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-55-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300832-56-8 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(4-methyl-1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300832-60-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(3-methyl-1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

10/826,743




RN 300832-64-8 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclobutyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A







RN 300832-66-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a (5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[[[(1R)-1,2,2-trimethylpropyl]amino]carbonyl]amino]-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 300832-67-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-(1H-pyrrol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 300832-71-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.







RN 300832-72-8 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.










RN 300832-74-0 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(2-amino-4-thiazolyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.







RN 300832-83-1 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.








RN 300832-85-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(3-methyl-1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.





RE.CNT 27      THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



10/826,743


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(combinations of active agents with p38 MAP kinase inhibitors,  
pharmaceutical compns., and use in treatment of cytokine-mediated  
diseases)

RN 300832-84-2 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16  
,16a-tetradecahydro-2-[[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-  
4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RE.CNT 7      THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/826,743

L5 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:950022 CAPLUS

DN 140:16973

TI Preparation of macrocyclic peptides which are active against hepatitis C virus

IN Llinas-Brunet, Montse; Gorys, Vida J.

PA Boehringer Ingelheim (Canada) Ltd., Can.


SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 320,978.  
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003224977	A1	20031204	US 2003-353894	20030129
	CA 2369711	AA	20030730	CA 2002-2369711	20020130
	US 2003181363	A1	20030925	US 2002-320978	20021217
PRAI	CA 2002-2369711	A	20020130		
	US 2002-320978	A2	20021217		
OS	MARPAT 140:16973				
GI					



I

AB Macrocyclic peptides I [R1 is OH or NHSO<sub>2</sub>R1A, where R1A is (cyclo)alkyl, alkylcycloalkyl, or aryl which are optionally substituted from 1 to 3 times with halo, cyano, nitro, alkoxy, etc.; R2 is cycloalkyl] or their pharmaceutically-acceptable salt were prepared as inhibitors of the HCV NS3 protease. Thus, I (R1 = OH, R2 = cyclopentyl) was prepared and shown to have IC<sub>50</sub> < 0.01 μM in the NS3-NS4A protease assay and EC<sub>50</sub> < 0.01 μM in the cell-based HCV RNA replication assay.

IT 572922-86-2P 572922-94-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of macrocyclic peptides active against hepatitis C virus)

RN 572922-86-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclopentylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-




10/826,743


6-[[ (cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 572922-94-2 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclohexylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-

10/826,743


6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



IT 572922-87-3P 572922-88-4P 572922-93-1P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

10/826,743

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocyclic peptides active against hepatitis C virus)


RN 572922-87-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[[2-[2-(cyclohexylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentylloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, monosodium salt, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




● Na



RN 572922-88-4 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-2-[[2-[2-(cyclopentylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 572922-93-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclopentylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentylloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, monosodium salt, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


10/826,743

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



PAGE 2-A

● Na




IT 300831-72-5P 300831-74-7P 300831-75-8P  
300831-76-9P 300831-77-0P 572922-92-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of macrocyclic peptides active against hepatitis C virus)

RN 300831-72-5 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)





RN 300831-74-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.







RN 300831-75-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-carboxy-7-methoxy-4-quinolinyl)oxy]-6-[[ (cyclopentyloxy) carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, 14a-methyl ester, monosodium salt, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.






● Na



RN 300831-76-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-(diazoacetyl)-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.










RN 300831-77-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(bromoacetyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 572922-92-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclopentylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.





L5 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:886572 CAPLUS

DN 140:122161

TI An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

AU Lamarre, Daniel; Anderson, Paul C.; Bailey, Murray; Beaulieu, Pierre; Bolger, Gordon; Bonneau, Pierre; Boes, Michael; Cameron, Dale R.; Cartier, Mireille; Cordingley, Michael G.; Faucher, Anne-Marie; Goudreau, Nathalie; Kawai, Stephen H.; Kukolj, George; Lagace, Lisette; LaPlante, Steven R.; Narjes, Hans; Poupert, Marc-Andre; Rancourt, Jean; Sentjens, Roel E.; St. George, Roger; Simoneau, Bruno; Steinmann, Gerhard; Thibeault, Diane; Tsantrizos, Youla S.; Weldon, Steven M.; Yong, Chan-Loi; Llinas-Brunet, Montse

CS Departments of Biological Sciences, Boehringer Ingelheim (Canada) Ltd, Laval, QC, H7S 2G5, Can.

SO Nature (London, United Kingdom) (2003), 426(6963), 186-189  
CODEN: NATUAS; ISSN: 0028-0836

PB Nature Publishing Group

DT Journal

LA English

AB Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at risk of developing significant morbidity and mortality. Current interferon-based therapies are suboptimal especially in patients infected with HCV genotype 1, and they are poorly tolerated, highlighting the unmet medical need for new therapeutics. The HCV-encoded NS3 protease is essential for viral replication and has long been considered an attractive target for therapeutic intervention in HCV-infected patients. Here we identify a class of specific and potent NS3 protease inhibitors and report the evaluation of BILN 2061, a small mol. inhibitor biol. available through oral ingestion and the first of its class in human trials. Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive reduction of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor. Our results further illustrate the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.

IT 300832-84-2, BILN 2061

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus)


RN 300832-84-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:648255 CAPLUS  
 DN 139:197768  
 TI Preparation of macrocyclic peptides active against the hepatitis C virus  
 IN Tsantrizos, Youla S.; Cameron, Dale R.; Faucher, Anne-Marie; Ghire, Elise;  
 Goudreau, Nathalie; Halmos, Teddy; Llinas-Brunet, Montse  
 PA Boehringer Ingelheim (Canada) Ltd., Can.  
 SO U.S., 90 pp., Cont.-in-part of U.S. Ser. No. 542,675, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6608027	B1	20030819	US 2001-760946	20010116
	EP 1437362	A1	20040714	EP 2004-9264	20000403
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	US 2004002448	A1	20040101	US 2003-358726	20030205
PRAI	US 1999-128011P	P	19990406		
	US 2000-542675	B2	20000403		
	EP 2000-913999	A3	20000403		
	US 2001-760946	A1	20010116		
OS	MARPAT 139:197768				
GI					



AB Macrocyclic peptides I [W = CH or N; R21 = H, halo, alkyl, cycloalkyl, haloalkyl, alkoxy, cycloalkoxy, hydroxy, or an amino group; R22 = H, halo, alkyl, cycloalkyl, haloalkyl, thioalkyl, alkoxy, cycloalkoxy, alkoxyalkyl, cycloalkyl, aryl or heteroaryl; R3 = hydroxy, NH2, aryl- or heteroarylamino, NHCOR32, CONHR32, CO2R32, where R32 is alkyl or cycloalkyl; D is a 5 to 10-atom saturated or unsatd. alkylene chain optionally containing one to three heteroatoms independently selected from: O, S, or NH or substituted imino; R4 = H or from one to three substituents at any carbon atom of chain D; A is an amide or carboxylic acid group or a pharmaceutically acceptable salt or ester; two diastereomers may exist at the cyclopropane moiety] were prepared which are active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus. Thus, macrocyclic peptide I [W = N; R21, R22, R4 = H; A = CO2H; R3CH-D = (S)-(Me3CO2CNH)CH(CH2)3CH:CH(CH2)2-E (syn to acid)] was prepared and showed IC50 > 0.1  $\mu$ M in the full-length NS3-NS4A heterodimer protein fluorogenic assay.


IT 300831-32-7P 300831-33-8P 300831-34-9P  
 300831-79-2P 300831-80-5P 300831-81-6P  
 300831-82-7P 300831-83-8P 300831-84-9P  
 300831-85-0P 300831-86-1P 300831-88-3P  
 300831-89-4P 300831-90-7P 300831-91-8P  
 300831-92-9P 300831-93-0P 300831-94-1P  
 300831-95-2P 300831-96-3P 300831-97-4P  
 300831-99-6P 300832-00-2P 300832-01-3P  
 300832-02-4P 300832-03-5P 300832-14-8P  
 300832-15-9P 300832-16-0P 300832-17-1P  
 300832-18-2P 300832-19-3P 300832-20-6P  
 300832-21-7P 300832-22-8P 300832-23-9P  
 300832-24-0P 300832-25-1P 300832-26-2P  
 300832-27-3P 300832-28-4P 300832-29-5P  
 300832-30-8P 300832-31-9P 300832-32-0P  
 300832-33-1P 300832-34-2P 300832-35-3P  
 300832-36-4P 300832-37-5P 300832-38-6P  
 300832-39-7P 300832-40-0P 300832-41-1P  
 300832-42-2P 300832-43-3P 300832-44-4P  
 300832-45-5P 300832-46-6P 300832-47-7P  
 300832-48-8P 300832-49-9P 300832-50-2P  
 300832-51-3P 300832-52-4P 300832-53-5P  
 300832-54-6P 300832-55-7P 300832-56-8P  
 300832-57-9P 300832-58-0P 300832-59-1P  
 300832-60-4P 300832-61-5P 300832-62-6P  
 300832-63-7P 300832-64-8P 300832-65-9P  
 300832-66-0P 300832-67-1P 300832-68-2P  
 300832-69-3P 300832-70-6P 300832-71-7P  
 300832-72-8P 300832-73-9P 300832-74-0P  
 300832-75-1P 300832-76-2P 300832-77-3P  
 300832-78-4P 300832-79-5P 300832-80-8P  
 300832-81-9P 300832-82-0P 300832-83-1P  
 300832-84-2P 300832-85-3P 300832-86-4P  
 300832-87-5P 300832-88-6P 300832-89-7P  
 300832-90-0P 300832-91-1P 300832-92-2P  
 300832-93-3P 300832-94-4P 300832-95-5P  
 300832-96-6P 300832-97-7P 300832-98-8P  
 300832-99-9P 300833-00-5P 300833-01-6P  
 300833-02-7P 301188-00-1P 572922-86-2P  
 572922-94-2P 577965-82-3P 577965-83-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of macrocyclic peptides active against the hepatitis C virus)


RN 300831-32-7 CAPLUS

CN 13aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxylic  
 acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-  
 1,2,3,5,6,7,8,9,12,12a,13,14,15,15a-tetradecahydro-2-[(7-methoxy-2-phenyl-  
 4-quinolinyl)oxy]-5,15-dioxo-, (2R,6S,10E,12aS,13aR,15aS)- (9CI) (CA  
 INDEX NAME)



RN 300831-33-8 CAPLUS


CN 13aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-, (2R,6S,12aR,13aR,15aS)- (9CI) (CA INDEX NAME)



RN 300831-34-9 CAPLUS


CN 13aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-, (2R,6S,12aS,13aR,15aS)- (9CI) (CA INDEX NAME)





RN 300831-79-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(4-quinolinyloxy)-, (2R,6S,10E,16aS)- (9CI) (CA INDEX NAME)




RN 300831-80-5 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-(acetylamino)-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(4-quinolinyloxy)-, (2R,6S,10E,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.


PAGE 1-A





RN 300831-81-6 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(4-quinolinyloxy)-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300831-82-7 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-4-quinolinyloxy)-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743




RN 300831-83-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300831-84-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300831-85-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aR,14aS,16aS)-(9CI) (CA INDEX NAME)





RN 300831-86-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-amino-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A






RN 300831-88-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,9,16-trioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300831-89-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300831-90-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-9-hydroxy-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300831-91-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,9,16-trioxo-, (2R,6S,12Z,13aR,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 300831-92-9 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-(acetylamino)hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 300831-93-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic


acid, 6-[[ (1,1-dimethylethoxy) carbonyl] amino]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[ (7-methoxy-2-(2-thiazolyl)-4-quinolinyl) oxy]-5,16-dioxo-, (2R,6S,12Z,13aR,14aR,16aS)-  
(9CI) (CA INDEX NAME)



RN 300831-94-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacycloheptadecine-16a(5H)-carboxylic acid, 6-[[ (1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,14,15,15a,16,17,18,18a-hexadecahydro-5,18-dioxo-2-(4-quinolinyl oxy)-, (2R,6S,18aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



RN 300831-95-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotridecine-12a(5H)-carboxylic acid, 6-[[ (1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,11a,12,13,14,14a-dodecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl) oxy]-5,14-dioxo-, (2R,6S,10E,11aR,12aR,14aS)- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


RN 300831-96-3 CAPLUS

CN Cyclopropanecarboxylic acid, N-[(1,1-dimethylethoxy) carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl) oxy]-L-prolyl-1-amino-2-[(1E)-3-hydroxy-1-propenyl]-, cyclic (1→3)-ether, (1R,2R)- (9CI)



10/826,743


(CA INDEX NAME)



RN 300831-97-4 CAPLUS

CN 15aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclohexadecine-15a-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,5,6,7,10,11,12,14a,15,16,17,17a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,17-dioxo-, (2R,6S,14aS,15aR,17aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



RN 300831-99-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotridecine-12a(5H)-carboxylic acid, 2-[[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,5,6,7,8,9,10,11,12,14a,15,16,17,17a-hexadecahydro-5,17-dioxo-, (2R,6S,11aS,12aR,14aS)- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


RN 300832-00-2 CAPLUS

CN 15aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclohexadecine-15a-carboxylic acid, 2-[[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,5,6,7,8,9,10,11,12,14a,15,16,17,17a-hexadecahydro-5,17-dioxo-, (2R,6S,13Z,14aS,15aR,17aS)- (9CI) (CA INDEX NAME)

10/826,743

Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 300832-01-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-(acetylamino)-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A









RN 300832-14-8 CAPLUS

CN Cyclopropanecarboxylic acid, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-L-norvalyl- (4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-(3-hydroxypropyl)-, cyclic (1→3)-ether, (1R,2R)- (9CI) (CA INDEX NAME)



RN 300832-15-9 CAPLUS


CN Cyclopropanecarboxylic acid, N2-[(1,1-dimethylethoxy)carbonyl]-L-lysyl- (4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-(2-aminoethyl)-, cyclic (1→3)-imine, (1R,2R)- (9CI) (CA INDEX NAME)



10/826,743


RN 300832-16-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4,9]triazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-11-methyl-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-17-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4,9]triazacyclopentadecine-14a(5H)-carboxylic acid, 11-acetyl-6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-18-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4,9]triazacyclopentadecine-14a(5H)-carboxylic acid, 11-benzoyl-6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-19-3 CAPLUS


CN Cyclopropa[n]pyrrolo[2,1-c][1,4,9]triazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300832-20-6 CAPLUS


CN Cyclopropa[n]pyrrolo[2,1-c][1,4,9]triazacyclopentadecine-14a(5H)-carboxylic acid, 9-acetyl-6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)-(9CI) (CA INDEX NAME)

10/826,743



RN 300832-21-7 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-(dimethylamino)-4-quinolinyl]oxy]-6-[[1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-22-8 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-hydroxy-2-(trifluoromethyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743




RN 300832-23-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(5-oxazolyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI)  
(CA INDEX NAME)



RN 300832-24-0 CAPLUS

CN Cyclopropanecarboxylic acid, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-[(1Z)-3-hydroxy-1-propenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI)  
(CA INDEX NAME)






10/826,743


RN 300832-25-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-26-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-27-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-(2-pyridinyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-28-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(2-thiazolyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 300832-29-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-(1-methylethyl)-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 300832-30-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-31-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-32-0 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-[2-(1-methylethyl)-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Chemical structure of compound 10, which is a complex molecule featuring a quinoline ring system, a thiazole ring, and a bicyclic amide structure. The quinoline ring has a methoxy group (MeO) at the 6-position and is connected at the 2-position to a thiazole ring. The thiazole ring has a propyl group (Pr-i) at the 4-position. The quinoline ring is also connected at the 3-position to a bicyclic amide structure. The bicyclic amide structure consists of a bicyclic core with a carboxylic acid group (CO<sub>2</sub>H) and a carbamate group (NH-C(=O)-OBu-t).

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[[[7-methoxy-2-(2-pyridinyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI)  
(CA INDEX NAME)




CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (1,1-dimethylethoxy) carbonyl] amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl) oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-35-3 CAPLUS


10/826,743

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-(2-thiazolyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI)  
(CA INDEX NAME)




RN 300832-36-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI)  
(CA INDEX NAME)




RN 300832-37-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1H-pyrrol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-38-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-39-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(3-methyl-1,2,4-oxadiazol-5-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-40-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[2-(1H-imidazol-1-yl)-7-methoxy-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 300832-41-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(6-methyl-2-pyridinyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300832-42-2 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-2-[[2-[2-(formylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-43-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]hexadecahydro-2-[[7-methoxy-2-(6-methyl-2-pyridinyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)





RN 300832-44-4 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(4-methyl-1H-imidazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300832-45-5 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-(1H-pyrrol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)-(9CI) (CA INDEX NAME)

10/826,743




RN 300832-46-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-[2-[(methoxycarbonyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 300832-47-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300832-48-8 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1-methyl-1H-imidazol-2-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-49-9 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(methoxymethyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743



RN 300832-50-2 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-methyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-51-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-(methylamino)-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743




RN 300832-52-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-[2-[(methylamino)carbonyl]amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-53-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(2-amino-4-thiazolyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-54-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(3,4-dihydro-2H-pyran-2-yl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-55-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-56-8 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(4-methyl-1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-57-9 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[2-[2-(formylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743



RN 300832-58-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(methoxycarbonyl) amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 300832-59-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(5-methoxy-2-pyridinyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




10/826,743




RN 300832-60-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(3-methyl-1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-61-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-9-methyl-5,16-dioxo-, (2R,6S,9R,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-62-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-9-methyl-5,16-dioxo-, (2R,6S,9S,13aR,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300832-63-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




10/826,743

RN 300832-64-8 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclobutyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




PAGE 2-B



RN 300832-65-9 CAPLUS

10/826,743

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[(2-methyl-1-oxopropyl)amino]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)





RN 300832-66-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[[[(1R)-1,2,2-trimethylpropyl]amino]carbonyl]amino]-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A








RN 300832-67-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1H-pyrrol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.





RN 300832-68-2 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[(cyclopentylcarbonyl)amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743





RN 300832-69-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentyloxy) carbonyl] amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A





RN 300832-70-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[1-(methylethoxy)carbonyl]amino]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 300832-71-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[1-(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.




PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 300832-72-8 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 300832-73-9 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-(methylamino)-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 300832-74-0 CAPLUS  
 CN Cyclopropa[el]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(2-amino-4-thiazolyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B



RN 300832-75-1 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
 acid, 2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-  
 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-  
 [[(2,2,3,3-tetramethylcyclopropyl)carbonyl]amino]-,  
 (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

10/826,743






RN 300832-76-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(2-thiazolyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A







RN 300832-77-3 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-(6-methyl-2-pyridinyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 300832-78-4 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[[[(1R)-1,2,2-trimethylpropyl]amino]carbonyl]amino]-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


10/826,743

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 300832-79-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.




PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 300832-80-8 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(methoxycarbonyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 300832-81-9 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-[2-[[[(2-methylpropoxy)carbonyl]amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 300832-82-0 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclobutyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-[2-[(1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 300832-83-1 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 300832-84-2 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 300832-85-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(3-methyl-1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B



RN 300832-86-4 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-9-methyl-5,16-dioxo-, (2R,6S,9R,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743




RN 300832-87-5 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A










RN 300832-88-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a (5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-(2-thiazolyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.






RN 300832-89-7 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclobutyloxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-(2-thiazolyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.








RN 300832-90-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-(1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.








RN 300832-91-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclobutyloxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-(1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.








RN 300832-92-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 300832-93-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentyloxy) carbonyl] amino]hexadecahydro-2-[[7-methoxy-2-(1H-pyrrol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.







RN 300832-94-4 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(2-amino-4-thiazolyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 300832-95-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy) carbonyl]amino]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.










RN 300832-96-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentyloxy) carbonyl] amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.







RN 300832-97-7 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentyloxy) carbonyl] amino]hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 300832-98-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclobutyloxy)carbonyl]amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 300832-99-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclobutyloxy)carbonyl]amino]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 300833-00-5 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy) carbonyl] amino] hexadecahydro-2-[[7-methoxy-2-[2-(methylamino)-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 300833-01-6 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]hexadecahydro-6-[[2-methylpropoxy)carbonyl]amino]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300833-02-7 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]hexadecahydro-6-[[2-methylpropoxy)carbonyl]amino]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)


10/826,743

acid, 6-[[[(cyclopentyloxy) carbonyl] amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]hexadecahydro-9-methyl-5,16-dioxo-, (2R,6S,9R,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 301188-00-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]hexadecahydro-10,11-dihydroxy-5,16-dioxo-2-(4-quinolinyl)oxy]-, (2R,6S,16aS)- (9CI) (CA INDEX NAME)




RN 572922-86-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclopentylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 572922-94-2 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclohexylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[ (cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.




PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 577965-82-3 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-[2-(cyclopropylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/826,743

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 577965-83-4 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclobutylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/826,743

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




IT 300831-48-5P 300831-49-6P 300831-54-3P  
300831-60-1P 300831-61-2P 300831-63-4P  
300831-64-5P 300831-69-0P 300831-70-3P  
300831-71-4P 300831-72-5P 300831-73-6P  
300831-74-7P 300831-75-8P 300831-76-9P  
300831-77-0P 300831-78-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of macrocyclic peptides active against the hepatitis C virus)


RN 300831-48-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,16aS)- (9CI) (CA INDEX NAME)




RN 300831-49-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(4-quinolinyl)oxy]-, methyl ester, (2R,6S,10E,16aS)- (9CI) (CA INDEX NAME)




RN 300831-54-3 CAPLUS

CN Cyclopropa[n]pyrrolo[2,1-c][1,4,9]triazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]hexadecahydro-2-[[7-methoxy-2-phenyl-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300831-60-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,9,16-trioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 300831-61-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,9,16-trioxo-, methyl ester, (2R,6S,12Z,13aR,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 300831-63-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, ethyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 300831-64-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, ethyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300831-69-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-9-methyl-5,16-dioxo-, methyl ester, (2R,6S,9R,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300831-70-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-amino-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-9-methyl-5,16-dioxo-, methyl ester, (2R,6S,9R,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.

PAGE 1-A






RN 300831-71-4 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-9-methyl-5,16-dioxo-, methyl ester, (2R,6S,9R,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300831-72-5 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)







RN 300831-73-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-amino-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, dihydrochloride, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A








● 2 HCl

RN 300831-74-7 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.






RN 300831-75-8 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-carboxy-7-methoxy-4-quinolinyl)oxy]-6-[[[(cyclopentyloxy) carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, 14a-methyl ester, monosodium salt, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.








● Na

RN 300831-76-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-(diazoacetyl)-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.







RN 300831-77-0 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(bromoacetyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.








RN 300831-78-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(2-amino-4-thiazolyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.






RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/826,743

L5 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2003:633516 CAPLUS  
DN 139:185670  
TI Pharmaceutical compositions for hepatitis C viral protease inhibitors  
IN Chen, Shirlynn; Mei, Xiaohui  
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA  
SO PCT Int. Appl., 73 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003066103	A1	20030814	WO 2003-US3380	20030205
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003195228	A1	20031016	US 2003-357919	20030204
	US 6828301	B2	20041207		
	CA 2472249	AA	20030814	CA 2003-2472249	20030205
	EP 1474172	A1	20041110	EP 2003-707713	20030205
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003007524	A	20041221	BR 2003-7524	20030205
	JP 2005518423	T2	20050623	JP 2003-565526	20030205
PRAI	US 2002-355694P	P	20020207		
	WO 2003-US3380	W	20030205		
OS	MARPAT 139:185670				
GI					



I



AB Disclosed are pharmaceutical compns. of hepatitis C viral protease inhibitors having improved bioavailability, and methods of using these compns. for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. These compns. include co-solvent systems, lipid based systems, solid dispersions and granulations, and all comprise the hepatitis C viral protease inhibitor, at least one pharmaceutically acceptable amine and optionally one or more addnl. ingredients. A composition contained I 4, tromethamine 3.2, water 44.8, ethanol 21.3, and propylene glycol 26.7 weight/weight%.

IT **300832-84-2**

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(pharmaceutical compns. for hepatitis C viral protease inhibitors)



RN 300832-84-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A





IT 300832-64-8 300832-66-0 300832-67-1  
 300832-69-3 300832-70-6 300832-71-7  
 300832-72-8 300832-73-9 300832-74-0  
 300832-76-2 300832-77-3 300832-78-4  
 300832-79-5 300832-80-8 300832-81-9  
 300832-83-1 300832-85-3 300832-86-4  
 572922-86-2 572922-94-2 577965-78-7  
 577965-82-3 577965-83-4


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical comps. for hepatitis C viral protease inhibitors)

RN 300832-64-8 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
 acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-  
 [[(cyclobutyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-  
 tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 300832-66-0 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[[[(1R)-1,2,2-trimethylpropyl]amino]carbonyl]amino]-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 300832-67-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-(1H-pyrrol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 300832-69-3 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 300832-70-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[[(1-methylethoxy)carbonyl]amino]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




10/826,743

RN 300832-71-7 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




10/826,743

RN 300832-72-8 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B






10/826,743

RN 300832-73-9 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-(methylamino)-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




10/826,743

RN 300832-74-0 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(2-amino-4-thiazolyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



10/826,743


RN 300832-76-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(2-thiazolyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




10/826,743

RN 300832-77-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(6-methyl-2-pyridinyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B







RN 300832-78-4 CAPLUS

CN Cyclopropa[el]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[[[(1R)-1,2,2-trimethylpropyl]amino]carbonyl]amino]-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 300832-79-5 CAPLUS

10/826,743


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 300832-80-8 CAPLUS

10/826,743


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(methoxycarbonyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 300832-81-9 CAPLUS

10/826,743


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-[2-[[[(2-methylpropoxy) carbonyl] amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



RN 300832-83-1 CAPLUS




10/826,743


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



RN 300832-85-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic

10/826,743


acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(3-methyl-1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B



RN 300832-86-4 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic

10/826,743

acid, 6-[[[(cyclopentyloxy) carbonyl]amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-9-methyl-5,16-dioxo-, (2R,6S,9R,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)






RN 572922-86-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclopentylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy) carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A








RN 572922-94-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclohexylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.







RN 577965-78-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclobutyloxy)carbonyl]amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.







RN 577965-82-3 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-[2-(cyclopropylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.








RN 577965-83-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclobutylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.





RE.CNT 2      THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



10/826,743

L5 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:610478 CAPLUS

DN 139:164979

TI Preparation of macrocyclic peptides which are active against hepatitis C virus

IN Llinas-Brunet, Montse; Gorys, Vida J.

PA Boehringer Ingelheim (Canada) Ltd., Can.

SO PCT Int. Appl., 42 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003064455	A2	20030807	WO 2003-CA89	20030124
	WO 2003064455	A3	20040205		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2369711	AA	20030730	CA 2002-2369711	20020130
	CA 2474035	AA	20030807	CA 2003-2474035	20030124
	EP 1472278	A2	20041103	EP 2003-700743	20030124
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003007297	A	20041221	BR 2003-7297	20030124
PRAI	CA 2002-2369711	A	20020130		
	WO 2003-CA89	W	20030124		
OS	MARPAT 139:164979				
GI					



AB Macrocyclic peptides I, [R1 is OH or NHSO2R1A, where R1A is (cyclo)alkyl, alkylcycloalkyl, or aryl which are optionally substituted from 1 to 3 times with halo, cyano, nitro, alkoxy, etc.; R2 is cycloalkyl] or their pharmaceutically-acceptable salt were prepared as inhibitors of the HCV NS3 protease. Thus, I (R1 = OH, R2 = cyclopentyl) was prepared and shown to have  $IC_{50} < 0.01 \mu M$  in the NS3-NS4A protease assay and  $EC_{50} < 0.01 \mu M$  in the cell-based HCV RNA replication assay.

IT 572922-86-2P 572922-94-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of macrocyclic peptides active against hepatitis C virus)


RN 572922-86-2 CAPLUS



CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclopentylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A








RN 572922-94-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclohexylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[ (cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.





IT 572922-87-3P 572922-88-4P 572922-93-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocyclic peptides active against hepatitis C virus)


RN 572922-87-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclohexylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[ (cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, monosodium salt, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




PAGE 2-A

● Na



RN 572922-88-4 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-2-[[2-[2-(cyclopentylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 572922-93-1 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclopentylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentylloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, monosodium salt, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



PAGE 2-A

● Na



IT 300831-72-5P 300831-74-7P 300831-75-8P


300831-76-9P 300831-77-0P 572922-92-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of macrocyclic peptides active against hepatitis C virus)

RN 300831-72-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300831-74-7 CAPLUS



CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.









RN 300831-75-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-carboxy-7-methoxy-4-quinolinyl)oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, 14a-methyl ester, monosodium salt, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








● Na

RN 300831-76-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-(diazoacetyl)-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.







RN 300831-77-0 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(bromoacetyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.








RN 572922-92-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(cyclopentylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.





L5 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:511084 CAPLUS  
 DN 139:69527  
 TI Preparation of macrocyclic compounds as inhibitors of hepatitis C virus  
 IN Campbell, Jeffrey Allen; Good, Andrew Charles  
 PA Bristol-Myers Squibb Company, USA  
 SO PCT Int. Appl., 225 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003053349	A2	20030703	WO 2002-US39926	20021213
	WO 2003053349	A3	20040115		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004038872	A1	20040226	US 2002-317451	20021212
	US 6867185	B2	20050315		
	EP 1455809	A2	20040915	EP 2002-795860	20021213
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRAI	US 2001-344080P	P	20011220		
	US 2002-382103P	P	20020520		
	WO 2002-US39926	W	20021213		
OS	MARPAT 139:69527				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to macrocyclic compds. I [R1 = (cyclo)alkyl; R2 = H, halo, alkyl, alkoxy, cycloalkoxy, (un)substituted aryl or heterocyclyl; R3 = H, halo, CF3, alkoxy, cycloalkoxy; R4 = NH2 or NHR6, where R6 is alkanoyl, alkylaminocarbonyl, or carbalkoxy; Q is a 3-9 atom (un)saturated alkylene chain optionally containing 1-3 heteroatoms O, S, SO, or SO2], including methods for their synthesis and use in pharmaceutical compns. for therapeutic or prophylactic prevention or treatment of hepatitis C virus (HCV) infection. Thus, 3,13-diazatricyclo[11.3.0.04,6]hexadec-7-ene derivative II was prepared by a multistep procedure and assayed for inhibition of HCV NS3/4A protease (IC50 < 5 µM).

IT 552334-92-6P 552334-94-8P 552334-96-0P  
 552334-98-2P 552334-99-3P

RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of macrocyclic compds. as inhibitors of hepatitis C virus)

RN 552334-92-6 CAPLUS

CN Carbamic acid, [(2R,6S,10E,11aS,12aR,14aS)-12a-[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,11a,12,12a,13,14,14


10/826,743

a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,14-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotridecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


RN 552334-94-8 CAPLUS

CN Carbamic acid, [(2R,6S,11E,12aS,13aR,15aS)-13a-[[[(cyclopropylsulfonyl)amino]carbonyl]-2,3,5,6,7,8,9,10,12a,13,13a,14,15,15a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-1H-cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 552334-96-0 CAPLUS


CN Carbamic acid, [(2R,6S,11Z,12aS,13aR,15aS)-13a-[[[(cyclopropylsulfonyl)amino]carbonyl]-2,3,5,6,7,8,9,10,12a,13,13a,14,15,15a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-1H-cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



10/826,743

RN 552334-98-2 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 552334-99-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide,  
6-amino-N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-  
tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-  
dihydrochloride, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A







IT 552334-93-7P 552334-95-9P 552334-97-1P

RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of macrocyclic compds. as inhibitors of hepatitis C virus)

RN 552334-93-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotridecine-12a(5H)-carboxamide, 6-amino-N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,11a,12,13,14,14a-dodecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,14-dioxo-, dihydrochloride, (2R,6S,10E,11aS,12aR,14aS)- (9CI) (CA INDEX NAME)


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 552334-95-9 CAPLUS

CN 13aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxamide, 6-amino-N-(cyclopropylsulfonyl)-1,2,3,5,6,7,8,9,10,12a,13,14,15,15a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-, dihydrochloride, (2R,6S,11E,12aS,13aR,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.



— Ph

● 2 HCl


RN 552334-97-1 CAPLUS

CN 13aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxamide, 6-amino-N-(cyclopropylsulfonyl)-1,2,3,5,6,7,8,9,10,12a,13,14,15,15a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-, dihydrochloride, (2R,6S,11Z,12aS,13aR,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—Ph

● 2 HCl


IT 300831-63-4P 300831-83-8P 552335-29-2P  
 552335-30-5P 552335-32-7P 552335-33-8P  
 552335-34-9P 552335-35-0P

RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of macrocyclic compds. as inhibitors of hepatitis C virus)


RN 300831-63-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, ethyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300831-83-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 552335-29-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotridecine-12a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,11a,12,13,14,14a-dodecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,14-dioxo-, ethyl ester, (2R,6S,10E,11aS,12aR,14aS)- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 552335-30-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotridecine-12a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,11a,12,13,14,14a-dodecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,14-dioxo-, (2R,6S,10E,11aS,12aR,14aS)- (9CI) (CA INDEX NAME)


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 552335-32-7 CAPLUS

CN 13aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,5,6,7,8,9,10,12a,13,14,15,15a-tetradecahydro-2-[(7-methoxy-2-phenyl-


10/826,743

4-quinolinyl)oxy]-5,15-dioxo-, ethyl ester, (2R,6S,11E,12aS,13aR,15aS)-  
(9CI) (CA INDEX NAME)




RN 552335-33-8 CAPLUS

CN 13aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxylic  
acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-  
1,2,3,5,6,7,8,9,10,12a,13,14,15,15a-tetradecahydro-2-[(7-methoxy-2-phenyl-  
4-quinolinyl)oxy]-5,15-dioxo-, ethyl ester, (2R,6S,11Z,12aS,13aR,15aS)-  
(9CI) (CA INDEX NAME)




RN 552335-34-9 CAPLUS

CN 13aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxylic  
acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-  
1,2,3,5,6,7,8,9,10,12a,13,14,15,15a-tetradecahydro-2-[(7-methoxy-2-phenyl-  
4-quinolinyl)oxy]-5,15-dioxo-, (2R,6S,11E,12aS,13aR,15aS)- (9CI) (CA  
INDEX NAME)



RN 552335-35-0 CAPLUS

CN 13aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,5,6,7,8,9,10,12a,13,14,15,15a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-, (2R,6S,11Z,12aS,13aR,15aS)- (9CI) (CA INDEX NAME)



IT 552335-03-2P 552335-04-3P 552335-05-4P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of macrocyclic compds. as inhibitors of hepatitis C virus)

RN 552335-03-2 CAPLUS

CN 13aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxamide, 6-amino-N-(cyclopropylsulfonyl)hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-, dihydrochloride, (2R,6S,12aR,13aR,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Ph

● 2 HCl

RN 552335-04-3 CAPLUS  
 CN Carbamic acid, [(2R,6S,13aR,14aR,16aS)-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]octadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




10/826,743

RN 552335-05-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, 6-amino-N-(cyclopropylsulfonyl)hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, dihydrochloride, (2R,6S,13aR,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



● 2 HCl

PAGE 1-B



IT 552335-00-9P 552335-01-0P 552335-02-1P  
552335-06-5P 552335-07-6P 552335-08-7P  
552335-09-8P 552335-10-1P 552335-12-3P




552335-13-4P 552335-14-5P 552335-15-6P  
 552335-16-7P 552335-17-8P 552335-18-9P  
 552335-19-0P 552335-20-3P 552335-23-6P  
 552335-24-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocyclic compds. as inhibitors of hepatitis C virus)


RN 552335-00-9 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[(7-methoxy-4-quinolinyl)oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 552335-01-0 CAPLUS

CN Carbamic acid, [(2R,6R,12Z,13aS,14aR,16aS)-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-2-[(7-methoxy-4-quinolinyl)oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 552335-02-1 CAPLUS

CN Carbamic acid, [(2R,6S,12aR,13aR,15aS)-13a-[[[(cyclopropylsulfonyl)amino]carbonyl]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-1H-cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 552335-06-5 CAPLUS

CN Carbamic acid, [(2R,6S,11Z,12aS,13aR,15aS)-13a-[[[(cyclobutylsulfonyl)amino]carbonyl]-2,3,5,6,7,8,9,10,12a,13,13a,14,15,15a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-1H-cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 552335-07-6 CAPLUS

CN Carbamic acid, [(2R,6S,12aR,13aR,15aS)-13a-[[[(cyclobutylsulfonyl)amino]carbonyl]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-1H-cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 552335-08-7 CAPLUS

CN Carbamic acid, [(2R,6S,13aR,14aR,16aS)-14a-[[[(cyclobutylsulfonyl)amino]carbonyl]octadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 552335-09-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-6-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 552335-10-1 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
,16,16a-hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
2-fluoroethyl ester (9CI) (CA INDEX NAME)




RN 552335-12-3 CAPLUS

CN Carbamic acid, [(2R,6S,13aR,14aR,16aS)-14a-[[[(cyclopropylsulfonyl)amino]ca  
rbonyl]octadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-  
dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-,  
2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)




RN 552335-13-4 CAPLUS

CN Carbamic acid, [(2R,6S,13aR,14aR,16aS)-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]octadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, tetrahydro-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)





RN 552335-14-5 CAPLUS



CN 13aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-13a-carboxamide, 6-[(cyclopropylacetyl)amino]-N-(cyclopropylsulfonyl)hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-, (2R,6S,12aR,13aR,15aS)- (9CI) (CA INDEX NAME)



RN 552335-15-6 CAPLUS  
 CN Carbamic acid, [(2R,6S,12aR,13aR,15aS)-13a-[[[(cyclopropylsulfonyl)amino]carbonyl]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-1H-cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 552335-16-7 CAPLUS  
 CN Carbamic acid, [(2R,6S,12aR,13aR,15aS)-13a-[[[(cyclopropylsulfonyl)amino]carbonyl]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-1H-cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecin-6-yl]-, (3S)-tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)




RN 552335-17-8 CAPLUS  
 CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
 ,16,16a-hexadecahydro-2-[[7-methoxy-2-[4-(1-methylethyl)-2-thiazolyl]-4-  
 quinolinyl]oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-  
 a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA  
 INDEX NAME)






RN 552335-18-9 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 552335-19-0 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-dioxo-2-(4-quinolinyl)oxy]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 552335-20-3 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-14a-[[ (methylsulfonyl) amino] carbonyl]-5,16-dioxo-2-(4-quinolinyl)oxy]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 552335-23-6 CAPLUS

CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-[[ (cyclopropylsulfonyl) amino] carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-dioxo-2-[[8-(trifluoromethyl)-4-quinolinyl]oxy]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 552335-24-7 CAPLUS  
 CN Carbamic acid, [(2R,6S,12Z,13aS,14aR,16aS)-14a-  
 [[[(cyclopropylsulfonyl)amino]carbonyl]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15  
 ,16,16a-hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-  
 thiazolyl]-4-quinolinyl]oxy]-5,16-dioxocyclopropa[e]pyrrolo[1,2-  
 a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX  
 NAME)



IT 300831-33-8P 300831-81-6P 300831-89-4P  
 300832-25-1P 300832-47-7P 300832-84-2P  
 552335-49-6P 552335-53-2P 552335-62-3P  
 552335-63-4P 552335-64-5P 552335-65-6P  
 552335-66-7P 552335-67-8P 552335-68-9P  
 552335-69-0P 552335-70-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

10/826,743

(preparation of macrocyclic compds. as inhibitors of hepatitis C virus)


RN 300831-33-8 CAPLUS

CN 13aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-, (2R,6S,12aR,13aR,15aS)- (9CI) (CA INDEX NAME)




RN 300831-81-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(4-quinolinyl)oxy]-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300831-89-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-25-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-47-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)






RN 300832-84-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A





RN 552335-49-6 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, ethyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI)  
(CA INDEX NAME)



RN 552335-53-2 CAPLUS


10/826,743

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(4-quinolinylloxy)-, ethyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 552335-62-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, ethyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 552335-63-4 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-amino-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, ethyl ester, dihydrochloride, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



PAGE 1-A



PAGE 1-B




PAGE 2-A

● 2 HCl


RN 552335-64-5 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, ethyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 552335-65-6 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-carboxy-7-methoxy-4-quinolinyl)oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, 14a-ethyl ester, monosodium salt, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 2-A

● Na


RN 552335-66-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-(diazoacetyl)-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, ethyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 552335-67-8 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(bromoacetyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, ethyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 552335-68-9 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, ethyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 552335-69-0 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-[2-[[[(1,1-dimethylethoxy)carbonyl](1-methylethyl)amino]-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, ethyl ester, (2R,6S,12Z,13aS,14aR,16aS)-.(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 552335-70-3 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-[2-[[[(1,1-dimethylethoxy)carbonyl](1-methylethyl)amino]-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B





L5 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:338309 CAPLUS

DN 139:143358

TI Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection

AU Tsantrizos, Youla S.; Bolger, Gordon; Bonneau, Pierre; Cameron, Dale R.; Goudreau, Nathalie; Kukolj, George; LaPlante, Steven R.; Llinas-Brunet, Montse; Nar, Herbert; Lamarre, Daniel

CS Departments of Chemistry and Biological Sciences Research and Development, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2G5, Can.

SO Angewandte Chemie, International Edition (2003), 42(12), 1356-1360  
CODEN: ACIEF5; ISSN: 1433-7851

PB Wiley-VCH Verlag GmbH & Co. KGaA

DT Journal

LA English

AB A novel class of selective inhibitors of the hepatitis C virus NS3 protease, an enzyme which is essential for viral replication in vivo, was developed. The inhibitors are based on the structure-activity relationship between a substrate-based peptidomimetic ligand and the HCV NS3 serine protease. The designed HCV inhibitor and its saturated analogs are the first inhibitors of the NS3 protease which inhibit HCV RNA replication in the cell-based replicon assay. In addition, they are orally absorbed and stable to metabolic breakdown. Thus, these compds. show many of the desirable properties of a druglike archetype and could lead to a clinically useful antiviral agent for the treatment of hepatitis C viral infections in humans.

IT 572918-62-8P 572918-63-9P 572918-64-0P


572918-65-1P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection)


RN 572918-62-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 572918-63-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 572918-64-0 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecane-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 572918-65-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,14aS,16aS)- (9CI) (CA INDEX NAME)

10/826,743



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/826,743

L5 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:725652 CAPLUS

DN 133:296659

TI Preparation of macrocyclic peptides active against the hepatitis C virus

IN Tsantrizos, Youla S.; Cameron, Dale R.; Faucher, Anne-marie; Ghio, Elise;  
Goudreau, Nathalie; Halmos, Teddy; Llinas-brunet, Montse

PA Boehringer Ingelheim (Canada) Ltd., Can.

SO PCT Int. Appl., 154 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059929	A1	20001012	WO 2000-CA353	20000403
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2367127	AA	20001012	CA 2000-2367127	20000403
	CA 2367127	C	20050118		
	EP 1169339	A1	20020109	EP 2000-913999	20000403
	EP 1169339	B1	20040929		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000009599	A	20020115	BR 2000-9599	20000403
	TR 200102878	T2	20020121	TR 2001-200102878	20000403
	EE 200100516	A	20021216	EE 2001-516	20000403
	NZ 515286	A	20040227	NZ 2000-515286	20000403
	EP 1437362	A1	20040714	EP 2004-9264	20000403
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	AT 277945	E	20041015	AT 2000-913999	20000403
	AU 778390	B2	20041202	AU 2000-35480	20000403
	RU 2247126	C2	20050227	RU 2001-129709	20000403
	ES 2230084	T3	20050501	ES 2000-913999	20000403
	ZA 2001007862	A	20040401	ZA 2001-7862	20010925
	BG 105970	A	20020531	BG 2001-105970	20011002
	HR 2001000720	A1	20021231	HR 2001-720	20011004
	NO 2001004857	A	20011031	NO 2001-4857	20011005
	HK 1042714	A1	20050401	HK 2002-104507	20020618
PRAI	US 1999-128011P	P	19990406		
	EP 2000-913999	A3	20000403		
	WO 2000-CA353	W	20000403		
OS	MARPAT 133:296659				
GI					



AB Macrocylic peptides I [W = CH or N; R21 = H, halo, alkyl, cycloalkyl, haloalkyl, alkoxy, cycloalkoxy, hydroxy, or an amino group; R22 = H, halo, alkyl, cycloalkyl, haloalkyl, thioalkyl, alkoxy, cycloalkoxy, alkoxyalkyl, cycloalkyl, aryl or heteroaryl; R3 = hydroxy, NH<sub>2</sub>, aryl- or heteroarylamino, NHCOR32, CONHR32, CO<sub>2</sub>R32; where R32 is alkyl or cycloalkyl; D is a 5 to 10-atom saturated or unsatd. alkylene chain optionally containing one to three heteroatoms independently selected from: O, S, or NH or substituted imino; R4 = H or from one to three substituents at any carbon atom of chain D; A is an amide or carboxylic acid group or a pharmaceutically acceptable salt or ester; two diastereomers may exist at the cyclopropane moiety] were prepared which are active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus. Thus, macrocylic peptide I [W = N; R21, R22, R4 = H; A = CO<sub>2</sub>H; R3CH-D = (S)-(Me<sub>3</sub>CO<sub>2</sub>CNH)CH(CH<sub>2</sub>)<sub>3</sub>CH:CH(CH<sub>2</sub>)<sub>2</sub>-E (syn to acid)] was prepared and showed IC<sub>50</sub> > 0.1 μM in the full-length NS3-NS4A heterodimer protein fluorogenic assay.

IT 300831-32-7P 300831-33-8P 300831-34-9P  
 300831-79-2P 300831-80-5P 300831-81-6P  
 300831-82-7P 300831-83-8P 300831-84-9P  
 300831-85-0P 300831-86-1P 300831-88-3P  
 300831-89-4P 300831-90-7P 300831-91-8P  
 300831-92-9P 300831-93-0P 300831-94-1P  
 300831-95-2P 300831-96-3P 300831-97-4P  
 300831-99-6P 300832-00-2P 300832-01-3P  
 300832-02-4P 300832-03-5P 300832-14-8P  
 300832-15-9P 300832-16-0P 300832-17-1P  
 300832-18-2P 300832-19-3P 300832-20-6P  
 300832-21-7P 300832-22-8P 300832-23-9P  
 300832-24-0P 300832-25-1P 300832-26-2P  
 300832-27-3P 300832-28-4P 300832-29-5P  
 300832-30-8P 300832-31-9P 300832-32-0P  
 300832-33-1P 300832-34-2P 300832-35-3P  
 300832-36-4P 300832-37-5P 300832-38-6P  
 300832-39-7P 300832-40-0P 300832-41-1P  
 300832-42-2P 300832-43-3P 300832-44-4P  
 300832-45-5P 300832-46-6P 300832-47-7P  
 300832-48-8P 300832-49-9P 300832-50-2P  
 300832-51-3P 300832-52-4P 300832-53-5P  
 300832-54-6P 300832-55-7P 300832-56-8P  
 300832-57-9P 300832-58-0P 300832-59-1P  
 300832-60-4P 300832-61-5P 300832-62-6P  
 300832-63-7P 300832-64-8P 300832-65-9P


300832-66-0P 300832-67-1P 300832-68-2P  
 300832-69-3P 300832-70-6P 300832-71-7P  
 300832-72-8P 300832-73-9P 300832-74-0P  
 300832-75-1P 300832-76-2P 300832-77-3P  
 300832-78-4P 300832-79-5P 300832-80-8P  
 300832-81-9P 300832-82-0P 300832-83-1P  
 300832-84-2P 300832-85-3P 300832-86-4P  
 300832-87-5P 300832-88-6P 300832-89-7P  
 300832-90-0P 300832-91-1P 300832-92-2P  
 300832-93-3P 300832-94-4P 300832-95-5P  
 300832-96-6P 300832-97-7P 300832-98-8P  
 300832-99-9P 300833-00-5P 300833-01-6P  
 300833-02-7P 301188-00-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocyclic peptides active against the hepatitis C virus)


RN 300831-32-7 CAPLUS

CN 13aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,5,6,7,8,9,12,12a,13,14,15,15a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-, (2R,6S,10E,12aS,13aR,15aS)- (9CI) (CA INDEX NAME)




RN 300831-33-8 CAPLUS

CN 13aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,15-dioxo-, (2R,6S,12aR,13aR,15aS)- (9CI) (CA INDEX NAME)




RN 300831-34-9 CAPLUS

CN 13aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyloxy)-5,15-dioxo-, (2R,6S,12aS,13aR,15aS)- (9CI) (CA INDEX NAME)



RN 300831-79-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(4-quinolinyloxy)-, (2R,6S,10E,16aS)- (9CI) (CA INDEX NAME)




RN 300831-80-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-(acetylamino)-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(4-quinolinylloxy)-, (2R,6S,10E,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B




RN 300831-81-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-




10/826,743

1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(4-quinolinyl oxy)-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300831-82-7 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300831-83-8 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743




RN 300831-84-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300831-85-0 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aR,14aS,16aS)- (9CI) (CA INDEX NAME)




RN 300831-86-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-amino-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




PAGE 1-B



RN 300831-88-3 CAPLUS


10/826,743

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,9,16-trioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300831-89-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300831-90-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-9-hydroxy-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300831-91-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,9,16-trioxo-, (2R,6S,12Z,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)





RN 300831-92-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-(acetamino)hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A





RN 300831-93-0 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(2-thiazolyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aR,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300831-94-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacycloheptadecine-16a(5H)-carboxylic acid, 6-[[ (1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,14,15,15a,16,17,18,18a-hexadecahydro-5,18-dioxo-2-(4-quinolinyl oxy)-, (2R,6S,18aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 300831-95-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotridecine-12a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,11a,12,13,14,14a-dodecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,14-dioxo-, (2R,6S,10E,11aR,12aR,14aS)- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 300831-96-3 CAPLUS

CN Cyclopropanecarboxylic acid, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-[(1E)-3-hydroxy-1-propenyl]-, cyclic (1→3)-ether, (1R,2R)- (9CI) (CA INDEX NAME)




RN 300831-97-4 CAPLUS

CN 15aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclohexadecine-15a-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,5,6,7,10,11,12,14a,15,16,17,17a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,17-dioxo-, (2R,6S,14aS,15aR,17aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

10/826,743



RN 300831-99-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotridecine-12a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,14-dioxo-, (2R,6S,11aS,12aR,14aS)- (9CI) (CA INDEX NAME)


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 300832-00-2 CAPLUS

CN 15aH-Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclohexadecine-15a-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,5,6,7,8,9,10,11,12,14a,15,16,17,17a-hexadecahydro-5,17-dioxo-, (2R,6S,13Z,14aS,15aR,17aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.



RN 300832-01-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-(acetylamino)-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-,




10/826,743


(2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 300832-02-4 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,10E,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743



RN 300832-03-5 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,10Z,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-14-8 CAPLUS


CN Cyclopropanecarboxylic acid, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-(3-hydroxypropyl)-, cyclic (1→3)-ether, (1R,2R)- (9CI) (CA INDEX NAME)

10/826,743




RN 300832-15-9 CAPLUS

CN Cyclopropanecarboxylic acid, N2-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-(2-aminoethyl)-, cyclic (1→3)-imine, (1R,2R)- (9CI) (CA INDEX NAME)



RN 300832-16-0 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4,9]triazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-11-methyl-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)



10/826,743


RN 300832-17-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4,9]triazacyclopentadecine-14a(5H)-carboxylic acid, 11-acetyl-6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-18-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4,9]triazacyclopentadecine-14a(5H)-carboxylic acid, 11-benzoyl-6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-19-3 CAPLUS

CN Cyclopropa[n]pyrrolo[2,1-c][1,4,9]triazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-20-6 CAPLUS


CN Cyclopropa[n]pyrrolo[2,1-c][1,4,9]triazacyclopentadecine-14a(5H)-carboxylic acid, 9-acetyl-6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-21-7 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[[2-[2-(acetylamino)-4-thiazolyl]-7-(dimethylamino)-4-quinolinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743




RN 300832-22-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-hydroxy-2-(trifluoromethyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-23-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(5-oxazolyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-24-0 CAPLUS

CN Cyclopropanecarboxylic acid, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-L-norvalyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-[(1Z)-3-hydroxy-1-propenyl]-, cyclic (1→3)-ether, (1R,2S)- (9CI)  
(CA INDEX NAME)



RN 300832-25-1 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-26-2 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743




RN 300832-27-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(2-pyridinyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300832-28-4 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(2-thiazolyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)






RN 300832-29-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-(1-methylethyl)-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-30-8 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-31-9 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743




RN 300832-32-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-[2-(1-methylethyl)-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-33-1 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-(2-pyridinyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-34-2 CAPLUS


10/826,743

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS;14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-35-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-(2-thiazolyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-36-4 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743




RN 300832-37-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1H-pyrrol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 300832-38-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 300832-39-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(3-methyl-1,2,4-oxadiazol-5-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-40-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[2-(1H-imidazol-1-yl)-7-methoxy-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-41-1 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-(6-methyl-2-pyridinyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300832-42-2 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[2-[2-(formylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)-(9CI) (CA INDEX NAME)

10/826,743



RN 300832-43-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-(6-methyl-2-pyridinyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-44-4 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(4-methyl-1H-imidazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743




RN 300832-45-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-(1H-pyrrol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300832-46-6 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-[2-[(methoxycarbonyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)-(9CI) (CA INDEX NAME)






RN 300832-47-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300832-48-8 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1-methyl-1H-imidazol-2-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300832-49-9 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(methoxymethyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

10/826,743



RN 300832-50-2 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-methyl-4-quinolinyl)oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-51-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-(methylamino)-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743




RN 300832-52-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-[2-[(methylamino)carbonyl]amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-53-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(2-amino-4-thiazolyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-54-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(3,4-dihydro-2H-pyran-2-yl)-7-methoxy-4-quinolinyl]oxy]-6-[[ (1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-55-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-56-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(4-methyl-1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-57-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[2-[2-(formylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-58-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(methoxycarbonyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300832-59-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(5-methoxy-2-pyridinyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-60-4 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(3-methyl-1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300832-61-5 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-9-methyl-5,16-dioxo-, (2R,6S,9R,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743




RN 300832-62-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-9-methyl-5,16-dioxo-, (2R,6S,9S,13aR,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300832-63-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-[2-[(1-methylethyl) amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)






10/826,743

RN 300832-64-8 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclobutyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




PAGE 2-B



RN 300832-65-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[(2-methyl-1-oxopropyl)amino]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)





RN 300832-66-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[[[(1R)-1,2,2-trimethylpropyl]amino]carbonyl]amino]-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A








RN 300832-67-1 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1H-pyrrol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.





RN 300832-68-2 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[(cyclopentylcarbonyl)amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)





RN 300832-69-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A






RN 300832-70-6 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[1-(methylethoxy)carbonyl]amino]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 300832-71-7 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[cyclopentyloxy]carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 300832-72-8 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 300832-73-9 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[{(cyclopentyloxy)carbonyl}amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-(methylamino)-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.




PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 300832-74-0 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(2-amino-4-thiazolyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B



RN 300832-75-1 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[[[(2,2,3,3-tetramethylcyclopropyl)carbonyl]amino]-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743






RN 300832-76-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(2-thiazolyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A






RN 300832-77-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(6-methyl-2-pyridinyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 300832-78-4 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[[[(1R)-1,2,2-trimethylpropyl]amino]carbonyl]amino]-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


10/826,743

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 300832-79-5 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 300832-80-8 CAPLUS  
 CN Cyclopropan[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-[2-[(methoxycarbonyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 300832-81-9 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-[2-[[[(2-methylpropoxy)carbonyl]amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.




PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 300832-82-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclobutyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 300832-83-1 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 300832-84-2 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 300832-85-3 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(3-methyl-1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




PAGE 2-B



RN 300832-86-4 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-9-methyl-5,16-dioxo-, (2R,6S,9R,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

10/826,743





RN 300832-87-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A








RN 300832-88-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-(2-thiazolyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.







RN 300832-89-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclobutyloxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-(2-thiazolyl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.










RN 300832-90-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-(1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.







RN 300832-91-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclobutyloxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-(1H-pyrazol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)-(9CI) (CA INDEX NAME).

Absolute stereochemistry.








RN 300832-92-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy) carbonyl] amino] hexadecahydro-2-[[7-methoxy-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 300832-93-3 CAPLUS

CN. Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentyloxy) carbonyl] amino]hexadecahydro-2-[[7-methoxy-2-(1H-pyrrol-1-yl)-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 300832-94-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(2-amino-4-thiazolyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 300832-95-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 300832-96-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentylmethoxy)carbonyl]amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 300832-97-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.










RN 300832-98-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclobutyloxy)carbonyl]amino]-2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 300832-99-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclobutyloxy) carbonyl] amino]hexadecahydro-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 300833-00-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]hexadecahydro-2-[[7-methoxy-2-[2-(methylamino)-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 300833-01-6 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-[2-(ethylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]hexadecahydro-6-[[2-(2-methylpropoxy)carbonyl]amino]-5,16-dioxo-, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300833-02-7 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic

acid, 6-[[[(cyclopentyloxy) carbonyl] amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]hexadecahydro-9-methyl-5,16-dioxo-, (2R,6S,9R,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 301188-00-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]hexadecahydro-10,11-dihydroxy-5,16-dioxo-2-(4-quinolinyl)oxy]-, (2R,6S,16aS)- (9CI) (CA INDEX NAME)



IT 300831-48-5P 300831-49-6P 300831-54-3P  
300831-60-1P 300831-61-2P 300831-63-4P  
300831-64-5P 300831-69-0P 300831-70-3P  
300831-71-4P 300831-72-5P 300831-73-6P  
300831-74-7P 300831-75-8P 300831-76-9P  
300831-77-0P 300831-78-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of macrocyclic peptides active against the hepatitis C virus)

RN 300831-48-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester,


10/826,743

(2R,6S,16aS)- (9CI) (CA INDEX NAME)




RN 300831-49-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,12,13,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(4-quinolin-2-yl)oxy]-, methyl ester, (2R,6S,10E,16aS)- (9CI) (CA INDEX NAME)




RN 300831-54-3 CAPLUS

CN Cyclopropa[n]pyrrolo[2,1-c][1,4,9]triazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]hexadecahydro-2-[(7-methoxy-2-phenyl-4-quinolin-2-yl)oxy]-5,16-dioxo]-, methyl ester, (2R,6S,13aR,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 300831-60-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,9,16-trioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 300831-61-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,9,16-trioxo-, methyl ester, (2R,6S,12Z,13aR,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300831-63-4 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, ethyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 300831-64-5 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-5,16-dioxo-, ethyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)





RN 300831-69-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-9-methyl-5,16-dioxo-, methyl ester, (2R,6S,9R,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)





RN 300831-70-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-amino-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-9-methyl-5,16-dioxo-, methyl ester, (2R,6S,9R,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A






RN 300831-71-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentyloxy) carbonyl] amino]-2-[(2-ethoxy-7-methoxy-4-quinolinyl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-9-methyl-5,16-dioxo-, methyl ester, (2R,6S,9R,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 300831-72-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)





RN 300831-73-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-amino-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, dihydrochloride, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A








● 2 HCl

RN 300831-74-7 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[7-methoxy-2-(methoxycarbonyl)-4-quinolinyl]oxy]-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.







RN 300831-75-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(2-carboxy-7-methoxy-4-quinolinyl)oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, 14a-methyl ester, monosodium salt, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








● Na

RN 300831-76-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-2-[[2-(diazoacetyl)-7-methoxy-4-quinolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 300831-77-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(bromoacetyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.








RN 300831-78-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[2-(2-amino-4-thiazolyl)-7-methoxy-4-quinolinyl]oxy]-6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, methyl ester, (2R,6S,12Z,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.









RE.CNT 1      THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:927005 CAPLUS  
 DN 141:395806  
 TI Preparation of quinoxalinyll macrocyclic hepatitis C serine protease inhibitors  
 IN Nakajima, Suanne; Sun, Ying; Tang, Datong; Xu, Gouyou; Porter, Brian; Or, Yat Sun; Wang, Zhe; Miao, Zhenwei  
 PA Enanta Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 131 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004093798	A2	20041104	WO 2004-US11841	20040416
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004266668	A1	20041230	US 2004-826743	20040416
PRAI	US 2003-418759	A	20030418		
	US 2003-509071P	P	20030418		
OS	MARPAT 141:395806				
GI					



AB The invention relates to macrocyclic compds. I [A is H, CO<sub>2</sub>R<sub>1</sub>, COR<sub>2</sub>, CONHR<sub>2</sub>, CSNHR<sub>2</sub> or SO<sub>2</sub>R<sub>2</sub>; G is OH, alkoxy, NHSO<sub>2</sub>R<sub>1</sub>, COR<sub>2</sub>, CO<sub>2</sub>R<sub>1</sub> or CONHR<sub>2</sub>; L is S, SCH<sub>2</sub>, SO<sub>2</sub>, O, COCH<sub>2</sub>, CHMeCH<sub>2</sub>, etc.; m, n = 0-2; p = 0-4; R<sub>2</sub> is a bond or H<sub>2</sub>; R<sub>1</sub> is H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or heterocycloalkyl; R<sub>2</sub> is any group given for R<sub>1</sub> or mono- or dialkylamino or -arylamino; R<sub>3</sub>, R<sub>4</sub> not defined; X and Y taken together with the carbon atoms to which they are

attached form (un)substituted aryl or heteroaryl; W is absent, O, S, NH, C(O)NR1 or NR1; Z is H, -CN, -SCN, -NCO, -NCS, NHNH2, N3, halo, cycloalkyl, aryl, etc.) or their pharmaceutically-acceptable salts, esters or prodrugs which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. The compds. of the invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. Thus, macrocycle II (Boc = tert-butoxycarbonyl) was prepared via peptide coupling and ring-closing metathesis reactions.

IT 787599-69-3P 787599-76-2P 787599-78-4P  
787599-80-8P 787599-82-0P 787599-84-2P  
787599-86-4P 787599-88-6P 787599-90-0P  
787599-92-2P 787599-94-4P 787599-96-6P  
787599-98-8P 787600-00-4P 787600-02-6P  
787600-04-8P 787600-06-0P 787600-08-2P  
787600-10-6P 787600-12-8P 787600-14-0P  
787600-16-2P 787600-18-4P 787600-20-8P  
787600-22-0P 787600-24-2P 787600-26-4P  
787600-28-6P 787600-30-0P 787600-32-2P  
787600-34-4P 787600-36-6P 787600-38-8P  
787600-40-2P 787600-42-4P 787600-44-6P  
787600-46-8P 787600-48-0P 787600-50-4P  
787600-52-6P 787600-54-8P 787600-56-0P  
787600-58-2P 787600-60-6P 787600-62-8P  
787600-64-0P 787600-66-2P 787600-68-4P  
787600-70-8P 787600-72-0P 787600-74-2P  
787600-76-4P 787600-78-6P 787600-81-1P  
787600-83-3P 787600-85-5P 787600-87-7P  
787600-90-2P 787600-92-4P 787600-94-6P  
787600-96-8P 787600-98-0P 787601-00-7P  
787601-02-9P 787601-04-1P 787601-06-3P  
787601-08-5P 787601-10-9P 787601-12-1P  
787601-14-3P 787601-16-5P 787601-18-7P  
787601-20-1P 787601-22-3P 787601-24-5P  
787601-26-7P 787601-28-9P 787601-30-3P  
787601-33-6P 787601-36-9P 787601-38-1P  
787601-40-5P 787601-42-7P 787601-44-9P  
787601-46-1P 787601-48-3P 787601-50-7P  
787601-52-9P 787601-54-1P 787601-56-3P  
787601-58-5P 787601-60-9P 787601-62-1P  
787601-64-3P 787601-66-5P 787601-68-7P  
787601-70-1P 787601-72-3P 787601-74-5P  
787601-76-7P 787601-78-9P 787601-80-3P  
787601-83-6P 787601-85-8P 787601-87-0P  
787601-89-2P 787601-91-6P 787601-93-8P  
787601-95-0P 787601-98-3P 787602-00-0P  
787602-02-2P 787602-05-5P 787602-07-7P  
787602-09-9P 787602-11-3P 787602-13-5P  
787602-15-7P 787602-17-9P 787602-19-1P  
787602-21-5P 787602-23-7P 787602-25-9P  
787602-27-1P 787602-29-3P 787602-31-7P  
787602-33-9P 787602-35-1P 787602-37-3P  
787602-39-5P 787602-41-9P 787602-43-1P  
787602-45-3P 787602-47-5P 787602-49-7P  
787602-51-1P 787602-54-4P 787602-56-6P  
787602-58-8P 787602-60-2P 787602-62-4P  
787602-64-6P 787602-66-8P 787602-68-0P  
787602-70-4P 787602-72-6P 787602-74-8P  
787602-76-0P 787602-78-2P 787602-80-6P  
787602-82-8P 787602-84-0P 787602-86-2P  
787602-88-4P 787602-90-8P 787602-92-0P

787602-94-2P 787602-96-4P 787602-98-6P  
 787603-00-3P 787603-02-5P 787603-04-7P  
 787603-06-9P 787603-08-1P 787603-10-5P  
 787603-12-7P 787603-14-9P 787603-16-1P  
 787603-18-3P 787603-20-7P 787603-23-0P  
 787603-26-3P 787603-28-5P 787607-50-5P  
 787607-51-6P 790229-08-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)


(preparation of quinoxalinylic cyclic peptides as hepatitis C serine protease  
 inhibitors)


RN 787599-69-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
 acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-  
 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-  
 thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.


PAGE 1-A






RN 787599-76-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[3-[2-(formylamino)-4-thiazolyl]-7-methoxy-2-quinoxalinyloxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787599-78-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[(3-ethyl-2-quinoxalinyloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 787599-80-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[(3-phenyl-2-quinoxalinyloxy)-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)]





RN 787599-82-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-(4-methoxyphenyl)-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A







RN 787599-84-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[3-(4-ethoxyphenyl)-2-quinoxalinyloxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.







RN 787599-86-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[3-(5-bromo-2-thienyl)-2-quinoxalinyloxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.









RN 787599-88-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[2-(3-pyridinyl)ethenyl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.







RN 787599-90-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[3-(3,4-dimethoxyphenyl)-2-quinoxalinyloxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.







RN 787599-92-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[2-(2-thienyl)ethenyl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.







RN 787599-94-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[3-(1H-indol-2-yl)-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.  
Double bond geometry unknown.






RN 787599-96-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-(1H-indol-3-ylmethyl)-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



RN 787599-98-8 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[3-(2-furanyl)-2-quinoxalinyloxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/826,743

Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 787600-00-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[3-(1H-benzimidazol-2-yl)-2-quinoxalinyloxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.


PAGE 1-A



PAGE 1-B




RN 787600-02-6 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-(1H-imidazol-2-ylmethyl)-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 787600-04-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(3-chloro-2-quinoxalinyloxy)-6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787600-06-0 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(3-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A









RN 787600-08-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(3-pyridinylethynyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.







RN 787600-10-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[3-(2,3-dihydro-5-benzofuranyl)-2-quinoxalinyloxy]-6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.





RN 787600-12-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-propynylamino)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787600-14-0 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[3-[ethyl(phenylmethyl)amino]-2-quinoxalinyloxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A




PAGE 1-B



RN 787600-16-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(3-pyridinylamino)-2-quinoxalinyl]oxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743




RN 787600-18-4 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(1H-tetrazol-1-yl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A







RN 787600-20-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-(4-morpholinyl)-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.







RN 787600-22-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(3-thienylmethoxy)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.







RN 787600-24-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-3-(2-thienyl)-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.









RN 787600-26-4 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[6-methoxy-3-(2-thienyl)-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.







RN 787600-28-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[6,7-dimethoxy-3-(2-thienyl)-2-quinoxalinyloxy]-6-[[ (1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.







RN 787600-30-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[6-cyano-3-(2-thienyl)-2-quinoxalinyloxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.








RN 787600-32-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[6-(1H-tetrazol-5-yl)-3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 787600-34-4 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-

10/826,743


1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[2-(2-thienyl)pyrido[2,3-b]pyrazin-3-yl]oxy]-, (2R,6S,13aS,14aR,16aS)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A





PAGE 1-B



RN 787600-36-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[7-(2-thienyl)-1,3-dioxolo[4,5-g]quinoxalin-6-yl]oxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.




RN 787600-38-8 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
 acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-  
 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-  
 thienyl)benzo[g]quinoxalin-2-yl]oxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



RN 787600-40-2 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[[6-(methylsulfonyl)-3-(2-thienyl)-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)-




10/826,743


(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 787600-42-4 CAPLUS

10/826,743


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[6-sulfo-3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 787600-44-6 CAPLUS

10/826,743


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[6-(hydroxymethyl)-3-(2-thienyl)-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 787600-46-8 CAPLUS

10/826,743


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[6-(1-piperidinylmethyl)-3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 787600-48-0 CAPLUS

10/826,743


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[6-nitro-3-(2-thienyl)-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 787600-50-4 CAPLUS

10/826,743


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[[6-amino-3-(2-thienyl)-2-quinoxalinyloxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 787600-52-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic


acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[6-  
[(phenylacetyl)amino]-3-(2-thienyl)-2-quinoxalinyloxy]-,  
(2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 2-B




10/826,743


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[6-(dimethylamino)-3-(2-thienyl)-2-quinoxalinyloxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 2-B



RN 787600-56-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic




10/826,743


acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[6-hydroxy-3-(2-  
thienyl)-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 787600-58-2 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic

10/826,743


acid, 6-[[{(1,1-dimethylethoxy)carbonyl]amino]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[6-(  
(phenylmethoxy)-3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 787600-60-6 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic

10/826,743


acid, 2-[[6-carboxy-3-(2-thienyl)-2-quinoxalinyloxy]-6-[[[(1,1-dimethylethoxy) carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 787600-62-8 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl]amino]-

10/826,743


1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[6-(phenylacetyl)-3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B








RN 787600-64-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[6-[[[(phenylmethyl)amino]carbonyl]-3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.






RN 787600-66-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[6-(2-phenylethyl)-3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 787600-68-4 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[6-bromo-3-(2-thienyl)-2-quinoxalinyloxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.

PAGE 1-A



PAGE 1-B






PAGE 2-B



RN 787600-70-8 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[6-(2-thiazolyl)-3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.






RN 787600-72-0 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[6-phenyl-3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI)

10/826,743


(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 787600-74-2 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[6-(3-  
pyridinylethynyl)-3-(2-thienyl)-2-quinoxalinyloxy]-,

10/826,743


(2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 2-A








RN 787600-76-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[6-(1H-pyrazol-1-yl)-3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.








RN 787600-78-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.








RN 787600-81-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclobutyloxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.








RN 787600-83-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclohexyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.







RN 787600-85-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[[[(3R)-tetrahydro-3-furanyl]oxy]carbonyl]amino]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.









RN 787600-87-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[[[(3S)-tetrahydro-3-furanyl]oxy]carbonyl]amino]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.





RN 787600-90-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[(cyclopentylcarbonyl)amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787600-92-4 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentylamino)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 787600-94-6 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentylamino)thioxomethyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/826,743

Double bond geometry unknown.


PAGE 1-A



PAGE 1-B




PAGE 2-B



RN 787600-96-8 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[(cyclopentylsulfonyl)amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743




RN 787600-98-0 CAPLUS



CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy) carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, 2-phenylethyl ester, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A








RN 787601-00-7 CAPLUS

CN Carbamic acid, [(2R,6S,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-dioxo-14a-[[[(2-phenylethyl)amino]carbonyl]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.








RN 787601-02-9 CAPLUS

CN Carbamic acid, [(2R,6S,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-dioxo-14a-[[[(2-phenylethyl)sulfinyl]amino]carbonyl]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.








RN 787601-04-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-acetic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro- $\alpha$ ,5,16-trioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.










RN 787601-06-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-acetic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro- $\alpha$ ,5,16-trioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, 2-phenylethyl ester, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.






RN 787601-08-5 CAPLUS


CN Carbamic acid, [(2R,6S,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-dioxo-14a-[oxo[(2-phenylethyl)amino]acetyl]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.


PAGE 1-A



PAGE 1-B



PAGE 2-B



RN 787601-10-9 CAPLUS


CN Carbamic acid, [(2R,6S,13aS,14aR,16aS)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-dioxo-14a-oxo[[[(phenylmethyl)sulfonyl]amino]acetyl]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/826,743

Double bond geometry unknown.


PAGE 1-A



PAGE 1-B




PAGE 2-B



RN 787601-12-1 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacycloheptadecine-16a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,12,13,15a,16,17,18,18a-hexadecahydro-5,11,18-trioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,15aS,16aR,18aS)- (9CI) (CA INDEX NAME)

10/826,743


Absolute stereochemistry.  
Double bond geometry unknown.



RN 787601-14-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacycloheptadecine-16a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,12,13,15a,16,17,18,18a-hexadecahydro-11-methyl-5,18-dioxo-2-[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,15aS,16aR,18aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 787601-16-5 CAPLUS

CN Cyclopropa[e]pyrrolo[2,1-i][1,7,10]oxadiazacyclohexadecine-15a(12H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,5,6,7,8,9,10,14a,15,16,17,17a-tetradecahydro-7-methyl-5,17-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,14aS,15aR,17aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 787601-18-7 CAPLUS

CN Cyclopropa[e]pyrrolo[2,1-i][1,7,10]thiadiazacyclohexadecine-15a(12H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,5,6,7,8,9,10,14a,15,16,17,17a-tetradecahydro-7-methyl-5,17-dioxo-2-

10/826,743

[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,14aS,15aR,17aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 787601-20-1 CAPLUS

CN Cyclopropa[e]pyrrolo[2,1-i][1,7,10]thiadiazacyclohexadecine-15a(12H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,5,6,7,8,9,10,14a,15,16,17,17a-tetradecahydro-7-methyl-5,17-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, 11-oxide, (2R,6S,14aS,15aR,17aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 787601-22-3 CAPLUS

CN Cyclopropa[e]pyrrolo[2,1-i][1,7,10]thiadiazacyclohexadecine-15a(12H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,5,6,7,8,9,10,14a,15,16,17,17a-tetradecahydro-7-methyl-5,17-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, 11,11-dioxide, (2R,6S,14aS,15aR,17aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 787601-24-5 CAPLUS



10/826,743

CN Cyclopropa[1]pyrrolo[1,2-h][1,8,11]thiadiazacyclooctadecine-17a(12H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,5,6,7,8,9,10,13,14,16a,17,18,19,19a-hexadecahydro-7-methyl-5,19-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,16aS,17aR,19aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 787601-26-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacycloheptadecine-16a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-11,11-difluoro-1,2,3,6,7,8,9,10,11,12,13,15a,16,17,18,18a-hexadecahydro-5,18-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,15aS,16aR,18aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 787601-28-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacycloheptadecine-16a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-11-fluoro-1,2,3,6,7,8,9,10,11,12,13,15a,16,17,18,18a-hexadecahydro-5,18-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,15aS,16aR,18aS)- (9CI) (CA INDEX NAME).

Absolute stereochemistry.  
Double bond geometry unknown.




RN 787601-30-3 CAPLUS

10/826,743


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[3-[2-(acetylamino)phenyl]-2-quinoxalinyloxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A




PAGE 1-B




RN 787601-33-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[(3-methyl-2-quinoxalinyloxy)-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 787601-36-9 CAPLUS



CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(phenylamino)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787601-38-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[(2-methylbenzoyl)amino]-5,16-dioxo-2-[[7-(2-thienyl)-1,3-dioxolo[4,5-g]quinoxalin-6-yl]oxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 787601-40-5 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
 acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-  
 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-  
 (methylphenylamino)-2-quinoxalinyloxy]-5,16-dioxo-,  
 (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




RN 787601-42-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[(phenylmethyl)amino]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 787601-44-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[[3-(butylamino)-2-quinoxalinyloxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787601-46-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(1-piperidinyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


10/826,743

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A




PAGE 1-B




RN 787601-48-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[3-(formylamino)-2-quinoxalinyloxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 787601-50-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(3,4-dihydro-3-oxo-2-quinoxalinyloxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787601-52-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[[3-[(1E)-2-(2-thienyl)ethenyl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as described by E or Z.


PAGE 1-A








RN 787601-54-1 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thiazolylamino)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 787601-56-3 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[(2-phenylethylamino)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787601-58-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-(imidazo[1,2-a]quinoxalin-4-yloxy)-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 787601-60-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[[3-(cyclohexylamino)-2-quinoxalinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 787601-62-1 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[[3-(cyclohexylamino)-2-quinoxalinyl]oxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743


acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-[(2-  
methoxyphenyl)amino]-2-quinoxalinyloxy]-5,16-dioxo-,  
(2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A





PAGE 1-B



RN 787601-64-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-  
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-[(3-  
methoxyphenyl)amino]-2-quinoxalinyloxy]-5,16-dioxo-,  
(2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 787601-66-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-[(4-methoxyphenyl)amino]-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787601-68-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-propenylamino)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787601-70-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[(3-hydroxy-2-methylbenzoyl)amino]-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 787601-72-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[(4-pyridinylcarbonyl)amino]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787601-74-5 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[[(2S)-hydroxyphenylacetyl]amino]-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


PAGE 1-A





RN 787601-76-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[(1H-indol-2-ylcarbonyl)amino]-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 787601-78-9 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[3-(2-thienyl)-2-quinoxalinyloxy]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743


NAME)

Absolute stereochemistry.  
Double bond geometry unknown.


PAGE 1-A



PAGE 1-B




PAGE 2-B



RN 787601-80-3 CAPLUS  
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[(3-  
thienylcarbonyl)amino]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-,




(2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787601-83-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(phenylmethyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 787601-85-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(phenylethynyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



10/826,743


RN 787601-87-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(3-benzo[b]thien-2-yl-2-quinoxalinyloxy)-6-[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 787601-89-2 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-[(4-methoxyphenyl)ethynyl]-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/826,743

Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 787601-91-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[(1E)-2-(2-thiazolyl)ethenyl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B




RN 787601-93-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[(1E)-2-(3-pyridinyl)ethenyl]-2-quinoxalinyl]oxy]-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B




RN 787601-95-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[(cyclopentylacetyl)amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.


PAGE 1-A




PAGE 1-B



PAGE 2-B



RN 787601-98-3 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[3-(5-ethenyl-2-thienyl)-2-quinoxalinyloxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)





RN 787602-00-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[5-(2-propenyl)-2-thienyl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A







RN 787602-02-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[[[(2-propenylamino)carbonyl]amino]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.








RN 787602-05-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[(3-pyridinylcarbonyl)amino]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787602-07-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[(3-thienylacetyl)amino]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.


PAGE 1-A




PAGE 1-B



PAGE 2-B



RN 787602-09-9 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-[(5-methyl-2-thiazolyl)amino]-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 787602-11-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[3-(2-benzothiazolylamino)-2-quinoxalinyloxy]-6-[[1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 787602-13-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(4-phenyl-1H-1,2,3-triazol-5-yl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 787602-15-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclobutylamino)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 787602-17-9 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[2-(2-propenyl)-5-(trimethylsilyl)-2H-1,2,3-triazol-4-yl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 787602-19-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[2-(2-propenyl)-2H-1,2,3-triazol-4-yl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.


PAGE 1-A



PAGE 1-B



RN 787602-21-5 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[[3-[(1E)-2-phenylethenyl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787602-23-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-[(1E)-2-(4-methoxyphenyl)ethenyl]-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as described by E or Z.

PAGE 1-A









RN 787602-25-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-[(1E)-2-(3-methyl-2-thienyl)ethenyl]-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as described by E or Z.





RN 787602-27-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[(1H-imidazol-4-ylcarbonyl)amino]-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787602-29-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[(1H-tetrazol-5-ylacetyl)amino]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 787602-31-7 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(3-pyridinyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


10/826,743

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 787602-33-9 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-(2-methyl-5-phenyl-2H-1,2,3-triazol-4-yl)-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 787602-35-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-(1-methyl-5-phenyl-1H-1,2,3-triazol-4-yl)-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A




PAGE 1-B



RN 787602-37-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(ethylamino)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743




RN 787602-39-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[ (5-methyl-3-isoxazolyl) carbonyl] amino]-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787602-41-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (2,4-dimethyl-5-thiazolyl) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 787602-43-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[(3-hydroxy-2-methylbenzoyl)amino]-5,16-dioxo-2-[[3-[(1E)-2-(3-pyridinyl)ethenyl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 787602-45-3 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-[(1E)-2-(1-methyl-1H-imidazol-2-yl)ethenyl]-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as described by E or Z.



PAGE 1-A



PAGE 1-B





RN 787602-47-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentylamino)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[(1Z)-2-(2-thienyl)ethenyl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 787602-49-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[5-(2-thiazolyl)-2-thienyl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.



RN 787602-51-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[[2-[(1-methylethyl)amino]-4-thiazolyl]carbonyl]amino]-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787602-54-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[[3-[(1E)-2-[4-(dimethylamino)phenyl]ethenyl]-2-quinoxalinyloxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B




RN 787602-56-6 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[(2-thiazolylamino)carbonyl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 787602-58-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[(3-[2,3'-bithiophen]-5-yl-2-quinoxalinyloxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 787602-60-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[(phenylmethylene)hydrazino]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 787602-62-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[(phenylamino)carbonyl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)



RN 787602-64-6 CAPLUS


10/826,743

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentylamino)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[(phenylamino)carbonyl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.


PAGE 1-A



PAGE 1-B




PAGE 2-B



10/826,743

RN 787602-66-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[(phenylamino)carbonyl]-2-quinoxalinyloxy]-6-[(3-thienylcarbonyl)amino]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787602-68-0 CAPLUS



CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclohexylamino)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A









RN 787602-70-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.





RN 787602-72-6 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[(1-pyrrolidinylcarbonyl)amino]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 787602-74-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[(1-piperidinylcarbonyl)amino]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

10/826,743





RN 787602-76-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(2-fluoroethyl)amino]carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.


PAGE 1-A






RN 787602-78-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[(2-thienylcarbonyl)amino]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787602-80-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-(benzoylamino)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787602-82-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[(1H-pyrrol-2-ylcarbonyl)amino]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787602-84-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787602-86-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[(3-furanylcarbonyl)amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787602-88-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(2,5-dimethyl-1H-pyrrol-3-yl)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787602-90-8 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787602-92-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[(1H-pyrazol-4-ylcarbonyl)amino]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787602-94-2 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[(2-furanylcarbonyl)amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 787602-96-4 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[(4-morpholinylcarbonyl)amino]-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 787602-98-6 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[[(2-hydroxy-1,1-dimethylethyl)amino]carbonyl]amino]-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



PAGE 1-A



PAGE 1-B




RN 787603-00-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[[(2-hydroxyethyl)amino]carbonyl]amino]-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 787603-02-5 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[[(3-hydroxypropyl)amino]carbonyl]amino]-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A




PAGE 1-B



PAGE 2-B



RN 787603-04-7 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic  
 acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-  
 (2-thienyl)-2-quinoxalinyloxy]-6-[(3-thienylsulfonyl)amino]-,  
 (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787603-06-9 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-[[[(1-methyl-1H-pyrazol-5-yl)amino]carbonyl]-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A







RN 787603-08-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 2-[[3-[[[4-bromo-2-thiazolyl]amino]carbonyl]-2-quinoxalinyloxy]-6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.







RN 787603-10-5 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[(2-thienylamino)carbonyl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.








RN 787603-12-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-[2-[(1-methylethyl)amino]-4-thiazolyl]-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.








RN 787603-14-9 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[ (cyclopentylamino) carbonyl] amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-[2-[(1-methylethyl) amino]-4-thiazolyl]-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.









RN 787603-16-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[3-(5-formyl-2-thienyl)-2-quinoxalinyloxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.






RN 787603-18-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[3-[(methylphenylamino)carbonyl]-2-quinoxalinyloxy]-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787603-20-7 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-phenylethyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 787603-23-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[(2-thienylcarbonyl)amino]-2-[[3-[(1Z)-2-(2-thienyl)ethenyl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787603-26-3 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[2-(2-thienyl)ethyl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.


PAGE 1-A



PAGE 1-B



RN 787603-28-5 CAPLUS  
 CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[3-[2-(formylamino)-4-thiazolyl]-2-quinoxalinyloxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)




RN 787607-50-5 CAPLUS


CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-[(1E)-2-(3-thienyl)ethenyl]-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.


PAGE 1-A






RN 787607-51-6 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-6-[(2-pyridinylcarbonyl)amino]-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)



RN 790229-08-2 CAPLUS

CN Hexitol, 1,4:3,6-dianhydro-2-deoxy-, [(2R,6S,13aS,14aR,16aS)-14a-carboxy-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]carbamate (9CI) (CA INDEX NAME)



IT 787599-67-1P 787599-74-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of quinoxalinylic cyclic peptides as hepatitis C serine protease inhibitors)


RN 787599-67-1 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-[[3-(2-thienyl)-2-quinoxalinyloxy]-, ethyl ester, (2R,6S,13aS,14aR,16aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A





RN 787599-74-0 CAPLUS

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[3-[2-(formylamino)-4-thiazolyl]-7-methoxy-2-quinoxalinyloxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, ethyl ester, (2R,6S,13aS,14aR,16aS)- (9CI)  
(CA INDEX NAME)

